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Chapter One 
Introduction to Contrast Agents for Magnetic Resonance Imaging 
1.1 Introduction 
 To obtain a doctoral degree in chemistry, I have investigated the physical and 
imaging-relevant properties of Eu
2+
-containing cryptates using a variety of techniques 
including magnetic resonance imaging (MRI), 
17
O NMR spectroscopy, and electron 
paramagnetic resonance (EPR) spectroscopy. In addition, I examined the stability of these 
cryptates towards transmetallation in the presence of biologically relevant metal ions. 
Finally, I studied the binding of a cryptate to human serum albumin to study the relaxivity–
molecular weight relationship for Eu
2+
-containing complexes. The results from all of these 
studies will be discussed throughout this thesis. This chapter describes the introductory 
material that will be necessary to appreciate my results. Specifically, I will describe ultra-
high field strength MRI, the properties of MRI contrast agents, and Eu
2+
-containing 
cryptates as candidates for use as contrast agents for MRI.  
1.2 Ultra-High Field Strength MRI 
MRI uses radiofrequency and magnetic fields to probe the chemical environment of 
water protons to produce images. This imaging technique is noninvasive because it does 
not require cutting or use harmful ionizing radiation to acquire images of the inside of 
opaque objects. The utility of this technique to study anatomical features stems from its 
inherent high spatial resolution [0.2–0.8 mm at 1.5–3 Tesla (T)]1 which makes MRI a 
widely used imaging technique for clinical and preclinical research as well as diagnostic 
medicine. Most medical imaging is performed at 1.5 and 3 T; however, working at ultra-
high fields (≥7 T) enables even higher resolution images (0.05 mm at 7 T) that can be used 
to study fine anatomical structures including senile plaques in Alzheimer’s disease.1 
2 
 
Furthermore, ultra-high fields enable the use of shorter acquisition times relative to 
working at lower field strengths (Figure 1.1).
1,2
  
 
Figure 1.1. MR images of a human brain taken at (a) 1.5 and (b) 7 T. Improvement in 
spatial resolution can be seen at 7 T that enables the detection of a cerebral microbleed 
(noted by the arrow). Reprinted with permission from ref. [3] Copyright (2011) John Wiley 
and Sons. 
1.3 Contrast Agents for MRI 
 Sometimes the contrast brought by MRI is not enough to differentiate pathological 
tissues from the surrounding healthy tissues. Therefore, contrast agents are used to further 
enhance image contrast by catalytically reducing the relaxation time of water protons in the 
vicinity of the contrast agents (Figure 1.2). 
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Figure 1.2 MR images of a mouse brain with an U87MG tumor taken before injection, 
directly after injection, and 2 min after the injection of gadolinium(III) 
diethylenetriaminepentaacetate (GdDTPA). The increased permeability of the vasculature 
in the tumor allows GdDTPA to diffuse into the tumor and resulted in the contrast 
enhancement.  Reprinted with permission from ref. [4] Copyright (2006) Elsevier. 
The ability of a contrast agent to influence the longitudinal relaxation rate (1/T1) of 
water protons is known as relaxivity (r1) and is expressed in units of mM
–1 
s
–1
. Relaxivity 
can be determined as the slope of a plot of proton longitudinal relaxation rate, 1/T1, versus 
the concentration of contrast agent. The relaxivity of common contrast agents, including 
Gd
3+
-based contrast agents, decreases as field strength increases, and in the ultra-high field 
regime, the efficiency of common contrast agents decreases considerably.
6
 This 
observation is demonstrated by the work of Weinmann and coworkers who measured the 
relaxivity of several Gd
3+
-based complexes including the clinically approved 
gadolinium(III) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (GdDOTA) and 5- 
[trisodium{4-(R)-[(4,4-diphenylcyclohexyl)phosphanooxymethyl]-3,6,9-tri-aza-3,6,9-tris 
(methoxycarbonyl)undecanedioato}gadolinium(III) (MS-325)–albumin at different field 
strengths (Figure 1.3).
7
 The relaxivity values decrease as the field strength increases, 
indicating that these Gd
3+
-based complexes become less efficient at higher fields. 
4 
 
 
Figure 1.3 Plots of relaxivity (37 °C, plasma) versus field strength for GdDOTA (left) and 
MS-325–albumin (right).7 
1.4 Factors Influencing the Efficiency of MRI Contrast Agents 
There are several parameters that are crucial to increasing relaxivity including the 
number of inner-sphere water molecules or the number of water molecules that is directly 
bound to the metal ion, q; the water-exchange rate or the rate at which inner-sphere water 
exchanges with bulk water, 1/τm; and the rotational-correlation rate or the rate at which the 
complex tumbles in solution, 1/τR. The way these molecular parameters affect the observed 
relaxivity of a contrast agent is well described by several intertwined equations known as 
the Solomon–Bloembergen–Morgan (SBM) equations (Eqs 1.1–1.4). It is clear from the 
SBM equations that relaxivity is influenced by numerous parameters.  
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For example, observed relaxivity is linearly dependent on the number of bound water 
molecules (Eq. 1.2). Therefore, to increase relaxivity, it is desirable for q to be as large as 
possible. However, increasing the number of inner-sphere water molecules by decreasing 
the denticity of the ligand generally increases the chance of demetallation. Because 
unchelated Gd
3+
 is toxic, the value of q needs to be as high as possible as long as the 
complex is stable to demetallation. In addition to q, the relaxivity of a Gd
3+
-containing 
complex is dependent on the bound-water-residency lifetime, τm, which is the reciprocal of 
the water-exchange rate. To increase relaxivity, the optimum value of the water-exchange 
rate between the inner-sphere water and the bulk solvent water should be slow enough for 
the metal ion to effectively influence the relaxation of water protons, but fast enough to 
allow the metal ion to interact with many water molecules. The water residency lifetime of 
bound water is interdependent on other parameters that include the rate at which the Gd
3+
-
containing complex rotates in solution. This rotational correlation rate is usually the 
limiting factor influencing relaxivity for small molecules including GdDOTA.  
 To obtain maximum relaxivity, the molecular parameters need to be simultaneously 
tuned so that the sum of the rotational correlation rate (1/τR), water-exchange rate (1/τm), 
and the electronic spin relaxation rate (1/T1e) is equal to that of the proton Larmor 
frequency, ωI, or the frequency at which the proton’s magnetic moment precesses at a 
given magnetic field strength (Eq 1.4). Because proton Larmor frequency is dependent on 
magnetic field strength (Figure 1.4), the optimum values for these molecular parameters 
also change as a function of field strength. 
Eq 1.5        
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Figure 1.4 Plot of proton Larmor frequency versus magnetic field strength. The proton 
Larmor frequency values were calculated using Eq 1.5. 
 There are two strategies that have been used to optimize values for rotational 
correlation rate (1/τR) and water-exchange rate (1/τm): (1) modifying the ligand such that 
the paramagnetic complex can bind to macromolecules thereby controlling the rotational 
correlation rate of the complex
8
 and (2) introducing steric bulk in the water-binding site in 
the metal complex to enable control of the water-exchange rate of the complex.
9 
Because 
most Gd
3+
-containing complexes have slow water-exchange rates (~10
6 
s
–1
),
10
 I took a 
slightly different approach—changing the metal from Gd3+ to Eu2+ and adapting the ligand 
modification strategies that work for Gd
3+
-based contrast agents. I used Eu
2+ 
as an 
alternative to Gd
3+
 to test the hypothesis that Eu
2+
 is an efficient contrast agent for ultra-
high-field-strength MRI. Eu
2+
 is isoelectronic with Gd
3+
, but differs in some molecular 
properties, including electronic spin relaxation rate and charge density, which in turn affect 
water-exchange rates. These molecular properties of Eu
2+
 can be tuned by changing the 
ligand structure using coordination chemistry principles based from the previous work with 
0
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Eu
2+
-containing complexes.
11
 The second chapter of my dissertation surveys the recent 
developments in the coordination chemistry of Eu
2+
 and applications of Eu
2+
-containing 
complexes including the potential use of these complexes as contrast agents for MRI. 
1.5 Eu
2+
-containing [2.2.2]cryptates 
 A promising feature of Eu
2+ 
that makes this ion an excellent candidate for use as a 
contrast agent for MRI is its lower charge density relative to Gd
3+
. A lower charge density 
makes Eu
2+
 to have a faster water-exchange rate than Gd
3+ 
(Table 1.1). However, research 
on Eu
2+
 chemistry in aqueous solution is limited because of the oxidative instability of 
Eu
2+
 in the presence of molecular oxygen. It has been demonstrated in the work of Allen 
and coworkers, where I was actively involved in synthesizing starting materials, that the 
divalent state of Eu can be stabilized using modified macrobicyclic ligands known as 
cryptands. Chelation of Eu
2+
 results in the formation of cryptates, which is the term for 
metalated cryptands. Using coordination chemistry principles—including Lewis basicity, 
steric bulk, cavity size, and hard–soft acid–base theory—the most oxidatively stable, 
aqueous Eu
2+
 complex reported was developed: the benzotetrathia[2.2.2] Eu
2+
-containing 
cryptate that is more oxidatively stable than Fe
2+
 in hemoglobin (Figure 1.5).
11 
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 Table 1.1 Comparison of Eu
2+
 to Gd
3+ 
in terms of charge, ionic radius, and water-
exchange rate. 
 Eu
2+ 
Gd
3+ 
Charge +2 +3 
Radius (pm)
12 
125 108 
Water-exchange rate (10
9
 s
–1
),
10
 [M(H2O)8]
x
 4.4 0.8 
Water-exchange rate (10
9
 s
–1
),
10
 [M(DTPA)(H2O)]
x
 1.3 0.033 
M = Gd
3+
 or Eu
2+
; x is the charge of the complex 
 
Figure 1.5 Plot of the anodic peak potentials of Eu
2+
 cryptates 1.1–1.6, the Eu2+ aqua ion, 
Fe
2+
 in hemoglobin, and water. A more positive potential means increased oxidative 
stability. Anodic peak potentials are reported as mean ± standard error of at least three 
measurements relative to Ag/AgCl.
11 
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In addition to stabilizing the divalent state of Eu, the unfunctionalized Eu
2+
-
containing [2.2.2]cryptate (Figure 1.6) was reported to have two inner-sphere water 
molecules and fast water-exchange rate (~10
8
 s
–1
).
13
 These favorable properties prompted 
me to hypothesize that Eu
2+
-containing crypates would be candidates for contrast agents at 
ultra-high field MRI. I investigated the contrast-enhancing ability of Eu
2+
-containing 
cryptates at different field strengths, temperature, and pH because these factors influence 
the relaxivity of contrast agents. The efficacy of Eu
2+
-containing cryptates at different 
temperatures and field strengths as well as the physical properties of Eu
2+
-containing 
cryptates are presented in the third chapter of this thesis.  
 
Figure 1.6 Chemical structure of the unfunctionalized Eu
2+
-containing [2.2.2]cryptate 1.7. 
Another critical feature that should be considered for complexes to be used as 
contrast agents for MRI is their stability towards demetallation. For contrast agents to be 
safe, they should be kinetically inert for at least long enough to be excreted. The stability 
towards demetallation is important for these Eu
2+
-containing cryptates because 
uncomplexed Eu
2+
 oxidizes easily, and Eu
3+
 is toxic.
14
 One possible pathway for 
dechelation of Eu
2+
 from a complex is by transmetallation induced by other ions. Ions that 
are found in blood plasma that could exchange with Eu
2+
 include Ca
2+
, Mg
2+
, and Zn
2+
.
14
 
These ions are of particular concern because of their abundance and their tendency to be 
complexed by ligands. Therefore, I examined the stability of several Eu
2+
-containing 
10 
 
cryptates towards transmetallation in the presence of Ca
2+
, Mg
2+
, and Zn
2+
, and the details 
of the transmetallation studies are presented in the fourth chapter of this document.  
The transmetallation studies demonstrated that amine-containing cryptates are inert 
to transmetallation, and because relaxivity tends to increase with molecular weight for 
these cryptates, I hypothesized that increasing the molecular weight by binding to human 
serum albumin produces a more efficient contrast agent. The fifth chapter of this thesis 
discusses the effect of the interaction of biphenyl cryptate 1.8 (Figure 1.7) with albumin 
and the resulting relaxometric properties of the cryptate.  
 
Figure 1.7 Chemical structure of the biphenyl-functionalized Eu
2+
-containing 
[2.2.2]cryptate 1.8. 
The final chapter summarizes my graduate research and discusses the future 
directions to establish relaxivity–molecular weight relationship for the Eu2+-containing 
cryptates using macromolecular and supramolecular systems and to evaluate the toxicity 
profile of these cryptates to assess their potential use for in vivo applications. 
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2.1 Introduction 
2.1.1 Properties of Eu
2+
 
Among the divalent lanthanides, Eu
2+
 has the most accessible divalent oxidation state 
because of its half-filled 4f
7 
electronic configuration and, consequently, a high stabilization 
from exchange energy (Figure 2.1).
1
 While Eu
2+
 is the most accessible of the divalent 
lanthanides, outside of the solid state it has a propensity to oxidize [reduction potential, 
Eu
o
(Eu
3+
/Eu
2+
) = –0.35 V vs normal hydrogen electrode (NHE)],2 which necessitates 
handling under an inert atmosphere. Four decades ago, there were only a few discrete Eu
2+
-
containing complexes reported. Most of these complexes were halides, chalcogenides, and 
organometallic compounds that are generally insoluble in organic solvents such as 
tetrahydrofuran (THF) because of the formation of extended structures.
3
  
 
 
 
Figure 2.1 Relative reduction potentials for Ln
3+→Ln2+ (V vs NHE).2 
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Despite oxidation and oligomerization presenting obstacles to the preparation and 
characterization of Eu
2+
-containing complexes, the interesting catalytic, photophysical, and 
magnetic properties of this ion have spurred a great deal of research. The unique properties 
of Eu
2+
 are influenced largely by the spacing of the energy levels of the 4f and 5d orbitals 
and the reducing properties of the ion. 
The f orbitals make the electronic properties of Eu
2+
 unique compared to elements 
in the d block. For example, using spectroscopic techniques, Adin and Sykes demonstrated 
that electron transfer from f orbitals is more difficult than from d orbitals.
4
 They observed a 
rate constant for the reaction of Eu
2+
 with V
3+
 of 0.013 M
–1 
s
–1
 (1.0 N HClO4, 25 °C, ionic 
strength of 2.0 M), while the reaction of Cr
2+
 with V
3+ 
under the same conditions is 0.85 
M
–1 
s
–1
.
4
 The smaller rate constant observed for Eu
2+
 relative to Cr
2+
 can be attributed to 
the valence 4f orbitals being shielded from the environment by the electrons in the fully 
occupied 5s and 5p orbitals. An additional influence of the f orbitals is exemplified by the 
photophysical properties of Eu
2+
 that stem from the lowest-energy and first-excited-state 
configurations of 4f
7
 and 4f
6
5d
1
, respectively.
5
 While the 4f orbitals of Eu
2+
 remain largely 
unperturbed by the presence of ligands, the energy of the 5d orbitals is influenced readily 
by ligands. Consequently, the luminescence properties of Eu
2+
 can be tuned using 
coordination chemistry, and the characteristic emission properties of this divalent ion 
include a broad emission band (390–580 nm)6 and a short radiative lifetime (~1 µs) that are 
attributed to the Laporte allowed 4f
6
5d
1→4f7 transitions.5 In addition to these allowed 
transitions, sharp emission bands, which appear between 354 and 376 nm,
7,8
 and longer 
radiative emission lifetimes (~1 ms) are observed that correspond to the Laporte forbidden 
4f→4f transitions, similar to those observed in the Eu3+ ion.5 Beyond the unique 
luminescence properties of Eu
2+
, the f orbitals are responsible for the interesting magnetic 
16 
 
characteristics of this divalent ion that include a high magnetic moment (7.63–8.43 µB) 
associated with seven unpaired electrons in an 
8
S7/2 ground-state configuration.
3,9 
In addition to the desirable optical and magnetic properties of Eu
2+
, this ion 
displays interesting redox chemistry. Divalent lanthanides including Eu
2+
 act as one-
electron reductants, and detailed discussions of the reductive chemistry of divalent 
lanthanides were published by Evans in 2000 and 2002.
2,10
 Since then, research efforts 
have been directed toward developing Eu
2+
-containing species that act as multielectron 
reductants in synthetic chemistry.
11
 Additionally, there is interest in studying the influence 
of ligands on the redox properties of Eu
2+
.
12
  
 
2.1.2 Early Eu
2+
 Complexes 
Discrete Eu
2+
-containing complexes were reported as early as 1964.
13
 However, the 
number of these complexes is small relative to their Eu
3+ 
analogues, which form air-stable 
complexes with most electronegative atoms such as oxygen and nitrogen, partially because 
Eu
3+
 is a hard Lewis acid. Eu
2+
 is a softer Lewis acid than Eu
3+
 because of its lower charge 
density; consequently, Eu
2+
-containing complexes often include ligands with relatively soft 
atoms such as carbon and phosphorous. 
Among the first discrete Eu
2+
-containing complexes prepared was the metallocene-like 
complex Cp2Eu, where Cp is cyclopentadiene. This complex did not garner much interest 
because of its insolubility in polar organic solvents such as THF.
14
 This insolubility was 
ascribed to a polymerization that can be prevented with the use of bulkier ligands.
9,14,15 
Templeton and coworkers were able to isolate crystals from THF or toluene of Cp*2Eu, 
2.1, where Cp* is methyl-substituted Cp (Figure 2.2).
9
 Evans and coworkers investigated 
the bond characteristics and the electronic spin–spin paramagnetic relaxation rate of Eu in 
Cp*2Eu(THF), 2.2, and Cp*2Eu(THF)(Et2O), 2.3. The Eu–ligand bonds of 2.2 and 2.3 are 
17 
 
ionic in character as indicated by the isomer shifts of these complexes: from 
151
Eu 
Mössbauer spectroscopy, a technique used to study the oxidation state and the local 
environment of Eu in the solid state, the shifts of 2.2 and 2.3 are not different from those of 
ionic Eu
2+ 
halide complexes.
16
 Moreover, the data obtained from the spherical relaxation 
model fits of the 
151
Eu Mössbauer spectra of the 2.2, 2.3, and [Cp*Eu(THF)2(µ-I)]2, 2.4, in 
the solid state indicate that the Eu–Eu distances affect the electronic spin–spin 
paramagnetic relaxation of these complexes, with longer Eu–Eu distances leading to 
slower spin–spin relaxation rates.16 In addition to Cp*, the sterically demanding ligand 
bis(trimethylsilyl)amide, [((CH3)3Si)2N]
–
, was used as a precursor in preparing Eu
2+
 
complexes. The six-coordinate complex [((CH3)3Si)2N]2Eu(CH3OCH2CH2OCH3)2, 2.5, 
and the four-coordinate complex [((CH3)3Si)2N]2Eu(bpy), 2.6, where bpy is 2,2’-
bipyridine, are both soluble in THF, pentane, toluene, and 1,2-dimethoxyethane (DME).
3 
In general, the problem of insolubility in hydrocarbons is addressed using sterically 
demanding ligands to increase hydrophobicity and to prevent the formation of coordination 
polymers.
9,14,15 
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Figure 2.2 Structures of Eu
2+
-containing complexes 2.1–2.15. 
Phosphine complexes of Eu
2+
 have been investigated since the early 1980s and display 
unique structural and electronic properties.
17–19
 In some cases, phosphorous-containing 
ligands form dative bonds with Eu
2+
 in the presence of oxygen-containing bases.
20
 
Templeton and coworkers reported the synthesis of phosphine complexes of Eu
2+
: in their 
procedure, NaEu[N(Si(CH3)3)2]3 was prepared from EuI2 and NaN(Si(CH3)3)2 in diethyl 
ether, and the relatively weak donor ligand [N(Si(CH3)3)2]
–
 was displaced by a 
19 
 
phosphorous-containing ligand such as 1,2-bis-(dimethylphosphino)ethane (DMPE) to 
give a complex with an empirical formula of Eu[N(Si(CH3)3)2]2(DMPE)1.5.
19
 Another 
Eu
2+
-containing phosphine complex was reported by the same group with Cp* in place of 
[N(Si(CH3)3)2]
–
. The resulting complex, EuCp*2(DMPE), 2.7, was not soluble in 
noncoordinating solvents, potentially because of the role of DMPE in bridging complexes 
to form coordination polymers. To reduce the potential for aggregation, ethylene-bridged 
DMPE was replaced with methylene-bridged 1,2-bis-(dimethylphosphino)methane 
(DMPM).
21 
The resulting complex EuCp*2(DMPM), 2.8, was isolated, but analogous 
complexes with monodentate phosphines such as P(CH3)3 or P(n-Bu)3 were not reported, 
likely because the steric bulk of these phosphines prevented the formation of a 
coordinatively saturated metal ion.
21
 Another Eu
2+
-containing phosphine complex was 
reported by Rabe and coworkers.
18
 Their four-coordinate, homoleptic Eu
2+
-containing 
phosphine complex Eu[(µ-P(t-Bu)2)2-Li(THF)]2, 2.9, assumes a heavily distorted 
tetrahedral geometry. The oxidation state of Eu in the complex was confirmed by 
151
Eu 
Mössbauer spectroscopy with an isomer shift of –11.7 mm s–1 as opposed to isomer shifts 
of 0–1 mm s–1 for compounds that contain Eu3+ (Figure 2.3).18 One interesting feature of 
this complex is that an alkali ion, Li
+
, interacts with phosphorous in P(t-Bu)2
 
and oxygen in 
THF similar to the complex NaEu[N(Si(CH3)3)2]3 where Na
+
 interacts with the nitrogen of 
[N(Si(CH3)3)2]
–
.
15,18
 Also, an agostic interaction between Eu
2+
 and the tert-butyl groups in 
P(t-Bu)2 was observed in 2.9.
18
 The authors postulated that this interaction is driven by the 
tendency of the metal to form a coordinatively saturated environment and also by crystal 
packing forces because this interaction is only observed in the solid state.
15,18
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Figure 2.3 
151
Eu Mössbauer spectrum of 2.9 at 4.2 K. Reprinted with permission from G. 
W. Rabe, G. P. A. Yap, A. L. Rheingold, Inorg. Chem. 1997, 36, 3212–3215. Copyright 
1997 American Chemical Society.  
In addition to the softer C- and P-containing ligands, polyoxadiazamacrobicyclic 
ligands (cryptands) form stable complexes (cryptates) of Eu
2+
, 2.10–2.13, which were first 
reported in the late 1970s. Cryptands are used to encapsulate Eu
2+
 to oxidatively stabilize 
this ion and enable studies of the luminescence properties of Eu
2+
. Gansow and coworkers 
demonstrated the oxidative stabilization of Eu
2+
 using cyclic voltammetry when the ion is 
bound by cryptands.
22
 This stabilization was attributed to a good fit of the Eu
2+
 ion in the 
cryptand cavity,
22
 and the thermodynamic stability constants (log K) for some Eu
2+
-
containing cryptates were reported by Burns and Baes to be 10.2–13.0.23 Besides the 
thermodynamic properties of these cryptates, these Eu
2+
-containing cryptates are 
substitutionally inert towards Na
+
, Ba
2+
, Ca
2+
, Mg
2+
, Zn
2+
, and tetraethylammonium 
cations.
24,25 
Beyond stabilizing the Eu
2+
 ion thermodynamically and kinetically, cryptands 
also exclude a large number of solvent molecules from the inner-sphere of the ion. This 
solvent exclusion is important because coordinated solvent molecules quench the 
21 
 
luminescence of Eu
2+
, thus this ion does not exhibit strong luminescence in aqueous 
solution at room temperature when not chelated.
26
 
In the 1990s, Eu
2+
 complexes with a wide variety of ligands were synthesized. 
Shore and coworkers reported Eu
2+
-containing
 
borohydrides (NH3)xEu(B10H14), 
(CH3CN)2Eu(BH4)2, and (C5H5N)1.8Eu(BH4)2 as precursors for preparing metal 
borides.
20,27
 However, all complexes that contain borohydrides are unstable as solids and 
tend to decompose to produce closo-[B10H10]
2–
.
20
 The conversion from Eu
2+
 borohydrides 
to Eu
2+
 borides was performed successfully at high temperatures (>200 °C) under vacuum 
to obtain the stable boride phase, EuB6.
27
 Although Eu
2+
-containing complexes with 
borohydrides as ligands were successfully synthesized, the coordination modes of Eu
2+
 in 
these complexes were not fully explored due to the lack of X-ray crystallographic data. In 
addition to Eu
2+
 borohydrides, Eu
2+
 selenolates and tellurolates were also prepared. For 
example, Eu[ESi(Si(CH3)3)3]2(TMEDA)2, 2.14, and {Eu[ESi(Si(CH3)3)3]2(DMPE)2}2(µ-
DMPE), 2.15, were reported by Arnold and coworkers where TMEDA is 
(CH3)2NCH2CH2N(CH3)2 and E is Se or Te.
28
 The crystal structure of 2.15 reveals a seven-
coordinate Eu
2+ 
ion
 
that is bridged by DMPE to form a dimeric complex that was not 
observed for the TMEDA-containing complex. The difference in coordination chemistry of 
the two complexes was attributed to the larger covalent radius of P relative to N and, 
consequently, a less crowded metal center in complex 2.15.
28  
The seminal studies of the coordination chemistry of Eu
2+
 from the 1960’s through 
the 1990’s built a foundation for the design of new ligands that will be driven by the 
functions of the resulting Eu
2+
-containing complexes. While Eu
2+
-containing clusters and 
polymers are reported in the literature,
29–33
 these compounds are not described in this 
chapter because the focus of this chapter is recent advances in the coordination chemistry 
22 
 
of discrete Eu
2+
 complexes. Synthetic strategies reported in the 21
st
 century are presented 
followed by a description of the reactivity and applications of the resulting Eu
2+
-containing 
complexes. 
2.2 Synthesis of Recent Eu2+-Containing Complexes 
The rapid increase in the reporting of Eu
2+
-containing complexes over the last two 
decades has resulted in the publication of several synthetic pathways to prepare these 
complexes (Scheme 2.1). These methods fall into three categories based on the europium-
based starting materials used: metallic europium;
 
europium(III) salts including halides, 
triflates, oxides, or nitrates; or europium(II) halides.
 
This section is organized based on 
these three types of starting materials: oxidation of Eu metal, reduction of Eu
3+
, and 
metathesis of Eu
2+
. 
Scheme 2.1 Synthetic methods for obtaining Eu
2+
-containing complexes arranged by 
source of europium where L is a ligand, N is either Hg or Sn, and M is an alkali metal ion. 
 
 
 
 
 
 
 
 
2.2.1 Oxidation of Eu
0
 
Oxidation of Eu metal can be accomplished by activation of Eu
0
 using Hg, iodine, or 
liquid ammonia; redox transmetallation; or pseudo-Grignard formation. It is crucial to 
23 
 
perform this type of synthesis under an inert atmosphere because Eu metal will oxidize 
uncontrollably in air to produce mixtures of Eu
2+
- and Eu
3+
-containing complexes.  
Syntheses of Eu
2+
 complexes from Eu
0
 often require activation. Mercury, which 
activates Eu
0
 through amalgamation, was used to prepare the homoleptic and tetranuclear 
Eu
2+
 complex Eu4[(t-Bu)2pz)]8, 2.16, where (t-Bu)2pz is 3,5-di-tert-butylpyrazolate 
(Figure 2.4).
34
 Structural elucidation of the linear complex 2.16 revealed different 
coordination modes (η2, µ-η5:η2, and µ-η2:η2) for the pyrazolates to Eu2+. The outer Eu2+ 
ions are bonded in a η2 fashion by the two terminal pyrazolates; a µ-η5:η2 coordination 
mode is observed for the four pyrazolates that bridge the inner and outer Eu
2+
 ions; and a 
µ-η2:η2 binding mode is exhibited by the two pyrazolates that bridge the two inner Eu2+ 
centers.
34 
24 
 
 
Figure 2.4 Structures of Eu
2+
-containing complexes 2.16–2.19, 2.21–2.28, 2.30–2.35, 
2.38, and 2.40 that were prepared from the oxidation of Eu
0
. 
An alternative to Hg as an activating agent is iodine, which was reported to be crucial 
in the preparation of several lanthanide-based complexes including the dimeric 
[Eu(Odip)(µ-Odip)(THF)2]2, 2.17, where Odip is 2,6-diisopropylphenolate.
35 
In addition to 
mercury and iodine, dissolution in liquid ammonia can be used in the activation of Eu
0
. 
Such is the case in the preparation of Eu
2+
-containing alkoxide Eu[OC6H3-2,6-(t-
25 
 
Bu)2]2(THF)3·0.75C7H8, 2.18, and aryloxides [Eu4(μ-OC10H7)6(OC10H7)2(THF)10]·2THF, 
2.19, and Eu(OC6H4OCH3)2, 2.20.
36–38
 Activation of Eu
0
 was also employed using liquid 
ammonia for the synthesis of {Eu2[(t-Bu)2pz)]4(THF)2} that is characterized by having 
centrosymmetric Eu
2+
 centers bonded in µ-η2:η5 and η2 modes by the bridging and terminal 
pyrazolate ligands, respectively.
39
 These coordination modes can also be found in 
pyrazolate-based Eu
2+
 complex 2.16 and demonstrate the ability of pyrazolate ligands to 
coordinatively saturate Eu
2+
. Liquid ammonia was also used in the one-pot synthesis of the 
organohydroborate complex of Eu
2+
 (THF)4Eu{(μ-H)2BC8H14}2, 2.21, that features an 
agostic interaction between Eu
2+
 and a hydrogen atom in one of the hydroborate ligands. 
Structural and IR data suggest the presence of agostic interaction in solution and solid 
state, and this interaction may have influenced the cis arrangement of the hydroborate 
ligands in the octahedral complex.
40 
The preparation of Eu
2+
 complexes through redox transmetallation sometimes uses 
mercury- and tin-based complexes as oxidants, and activating agents such as Hg are used 
to improve the yields of this type of synthesis. The preparation of the 
(perfluoroaryl)europium(II) complex Eu(C6F5)2(OC4H8)5, 2.22, entails the oxidation of Eu
0
 
using bis(pentafluorophenyl)mercury, Hg(C6F5)2, in THF. Complex 2.22, characterized by 
a pentagonal bipyramidal geometry with axial C6F5 groups and five THF molecules in the 
equatorial position, has relatively long Eu–C bonds (2.82 Å) that are likely due to the 
inductive electron-withdrawing effect of the fluorine substituents of the two phenyl 
groups.
41
 The same oxidant, Hg(C6F5)2, was used to prepare the homoleptic and dinuclear 
{Eu(i-Pr2pz)2(i-Pr2pzH)2}2, 2.23, where i-Pr2pz is 3,5-diisopropylpyrazolate. An x-ray 
crystal structure of the pyrazolato Eu
2+
 complex 2.23 shows a different coordination mode 
(µ-η5:η1) to Eu2+ by the bridging 3,5-diisopropylpyrazolates centers. This coordination 
26 
 
mode of the bridging pyrazolates in addition to the η1 binding mode of the terminal 
pyrazolates was ascribed to intramolecular hydrogen binding.
42
 It is worth noting that 
redox transmetallation reactions carried out in nonpolar solvents including toluene (for 
example, in the preparation of complex 2.23) can produce homoleptic Eu
2+
 complexes. In 
addition to complexes 2.22 and 2.23, Hg(C6F5)2 was used as oxidant in the preparation of 
Eu
2+
-containing complexes with triazanides as ligands [Dmp(Tph)N3EuC6F5], 2.24, and 
[Eu{N3Dmp(Tph)}2], 2.25 where Dmp is 2,6-(2,4,6-(CH3)3C6H2)2C6H3 and Tph is 2-
(2,4,6-i-Pr3C6H2)C6H4. Of particular note are the coordination modes of the terphenyl and 
biphenyl groups in complexes 2.24 and 2.25 that exhibit -arene–Eu interactions with Eu–
C distances of 3.088–3.233 and 3.011–3.311 Å in complex 2.24 and 2.25, respectively. In 
complex 2.24, both the mesityl ring of the terphenyl group and the triisopropylphenyl ring 
of the biphenyl moiety show an 5 interaction with the metal, whereas in complex 2.25, the 
mesityl rings of terphenyl groups exhibit 5 and 3 binding modes. The assignment of 
hapticity was based on the shortest metal–centroid separation or the smallest angle of the 
M–centroid vector and the normal of the arene plane.43,44  
When Hg(SCN)2 was used as oxidant, [Eu(NCS)2(DME)3], 2.26, was obtained from 
redox transmetallation with Eu
0
 in DME, and bimetallic [Eu(NCS)2(THF)4]2, 2.27, was 
obtained when THF was used as solvent. The crystal structure of the eight-coordinate 2.26 
shows configurational isomers, and the relative amount of each isomer is dependent on 
temperature. Racemic mixtures in a single crystal can be obtained at lower temperature (5 
°C) while a mixture of enantionamerically pure Λ (left hand) or Δ (right hand) products 
was observed in a single crystal at room temperature.
45
 The coordination environment in 
2.27 features bridging two thiocyanate ligands and terminal THF molecules, adapting a 
distorted pentagonal bipyramidal geometry in each Eu
2+
 center.  
27 
 
Besides mercury-based oxidants, trialkyltin(IV) compounds were explored for redox 
transmetallation with Eu
0
. Either the trivalent [Eu
3+
(Ph2pz)3(DME)2]·2DME, 2.28, or the 
divalent cis-[Eu
2+
(Ph2pz)2(DME)2], 2.29, can be made from the reaction of 
Sn(CH3)3(Ph2pz), where Ph2pz is 3,5-diphenylpyrazolate, with Eu
0
 in DME by changing 
the amount of excess Eu
0
.
46,47 
In contrast to redox transmetallation, the route toward the formation of a pseudo-
Grignard compound has been successful in preparing Eu
2+
 complexes even without the use 
of Hg, iodine, or ammonia. Thiolate-containing complex Eu(SAr*)2(THF)0.5, 2.30, where 
Ar*
 
is 2,6-(2,4,6-(i-Pr)3C6H2)2C6H3 was prepared from Eu
0
, Ar*SH, and 2-
iodobenzotrifluoride.
48
 This thiolate complex is characterized by η6-π interactions of Eu2+ 
with two o-2,4,6-triisopropylphenyl rings of the terphenyl groups as evidenced by IR 
spectroscopy and X-ray crystallography.
48
 Another example of a Eu
2+
-containing complex 
that shows η1-π interactions with Eu2+ and was prepared from europium metal is 
Eu(Dpp)(THF)2, 2.31, where Dpp is 2,6-Ph2C6H3. Complex 2.31 was synthesized from Eu
0
 
and DppI in THF and exhibits a distorted tetrahedral geometry with two aryl ligands and 
two THF molecules.
49 
While the oxidation of Eu
0
 through activation of the metal surface, redox 
transmetallation, and formation of pseudo-Grignard compounds are used to prepare 
homometallic Eu
2+
 complexes, charged-separated and neutral heterobimetallic Eu
2+
-
containing complexes can also be synthesized from Eu
0
. Treatment of Eu
0
 and another 
lanthanide metal (Y
0
, Nd
0
, or Ho
0
) with 2,6-diphenylphenol (OHdpp) at elevated 
temperature (190 °C) in the presence of Hg yielded charged-separated complexes, 
[Eu2(Odpp)3][Y(Oddp)4], 2.32; [Eu2(Odpp)3][Nd(Oddp)4], 2.33; and 
[Eu2(Odpp)3][Ho(Oddp)4], 2.34. The Eu
2+
 centers in the [Eu2(Odpp)3]
+
 are bridged by 
28 
 
aryloxide ligands and have coordination modes of η4:η2:η1 and η1:η6:η3 with π-arene–Eu 
interactions.
50
 In contrast to the charged-separated complexes, heterobimetallic complexes 
[CaEu(Oddp4)], 2.35; [SrEu(Oddp)4], 2.36; and [BaEu(Oddp)4], 2.37, were produced upon 
reaction of Eu
0
 and an alkaline-earth metal (Ca
0
, Sr
0
, or Ba
0
) with OHdpp at high 
temperatures (210–235 °C). However, when Eu0 was reacted with HOdpp in the presence 
of MOdpp (M = Na
0
, K
0
, and Li
0
) at elevated temperature (210 °C), heterobimetallic Eu
2+
-
containing complexes [NaEu(Oddp)3]·PhCH3, 2.38, and [KEu(Oddp)3]·2.5PhCH3, 2.39, 
and the mixed-valent complex [Eu2(Oddp)3][Eu(Oddp)4], 2.40, were obtained. These 
heterobimetallic complexes also show π-arene–Eu interactions that coordinatively saturate 
Eu
2+
. The coordination mode of the Eu
2+
 center is similar for 2.35 and 2.36 (η2:η3) while a 
different binding mode was observed in 2.37 (η3:η5). The coordination modes in the Eu2+-
containing complexes with alkaline metals are η4:η2:η1 (complex 2.38) and η3:η1:η1 
(complex 2.39) and are similar to that of [Eu2(Odpp)3]
+
 in the charged-separated 
complexes 2.32–2.34.51 Structural data for the [Eu2(Oddp)3]
+
 unit in 2.40 depict the 
aryloxides binding in η1:η4:η2 and η
3
:η2:η3 fashions.51 Purification of charged-separated or 
heterobimetallic complexes requires solvent extraction to remove the unreacted metal and 
homometallic coproducts.
50,51
 
Despite of the propensity of Eu metal to undergo uncontrolled oxidation to both Eu
2+
 
and Eu
3+
, the use of Eu metal can produce modest to excellent yields (23–96%) in the 
preparation of Eu
2+
-containing complexes. Also, activating Eu
0
 using Hg has been shown 
to increase the yield of the desired Eu
2+ 
complexes. 
2.2.2 Reduction of Eu
3+
 
The reduction of Eu
3+
 by either a ligand that is also a reductant or by chemical or 
electrochemical methods is more common than the oxidation of Eu metal. Eu
3+
 halides, 
29 
 
triflates, oxides, or nitrates are typically used as the precursors for the preparation of Eu
2+
-
containing complexes with a variety of ligands including aryloxides, aminodiboranates, 
crown ethers, and cryptands.
25,52–58
 An example of a Eu
2+
-containing complex that was 
prepared from Eu
3+
 chlorides with a reducing species is the dinuclear, distorted pentagonal 
bipyramidal complex {Eu(H3BN(CH3)2BH3)2(THF)2}2, 2.41, which used N,N-
dimethylaminodiboranate as the reductant (Figure 2.5).
52
 However, the preparation of 2.41 
produced mixtures of divalent and trivalent species.
52
 In contrast, only divalent species 
were obtained when EuI2 was used as a precursor instead of EuCl3.
52
 Qi and coworkers 
used Eu
3+
 chlorides as starting materials and a Na–K alloy as reductant to prepare 
[LEu(HMPA)2]2(THF)4, 2.42, where L is 2,2’-methylene bis(6-t-butyl-4-methylphenoxo) 
and HMPA is hexamethylphosphoric triamide. Complex 2.42 is characterized by two 
phenolate moieties bridging two Eu
2+
 atoms.
53
 Each Eu
2+
 in 2.42 adopts a distorted trigonal 
bipyramidal geometry and a slightly asymmetric bridging mode of the phenolate ligand. 
This asymmetry is also observed in the bond length of Eu–O, where the axial Eu–O bond 
(2.44 Å) is shorter than the equatorial Eu–O bond (2.52 Å).53 Also, the variation of the Eu–
O–C angles in 2.42 have been associated with the existence of agostic interaction in this 
coordinatively unsaturated complex.
53
 In addition to the use of Na–K alloy as a 
noncoordinating reductant in the preparation of Eu
2+
-containing complexes, Zn was used 
as reductant in the synthesis of complexes 2.10 and Eu
2+–18-crown-6, 2.43, from Eu3+ 
triflate.
54
 The reduction of Eu
3+
 by Zn in the presence of 18-crown-6 or [2.2.2]cryptand 
was monitored using the absorption bands at 250 and 330 nm, which were assigned to the 
Eu
2+
 species.
54
 Additionally, Eu
3+
 oxides serve as starting materials for preparing Eu
2+
-
containing complexes using electrochemical reduction. For example, Eu2O3 was reduced 
electrochemically in the syntheses of the Eu
2+
 complex of benzo-18-crown-6 and of 
30 
 
triethanolamine.
55,56
 With the reduction of Eu
3+
 strategy, our laboratory prepared several 
Eu
2+
-containing cryptates, 2.10, 2.11, and 2.44–2.47.57 In general, the advantage of using 
the reduction approach is that the metal source is air-stable, so the problem of surface 
oxidation is avoided. Nevertheless, the possibility of incomplete reduction of Eu
3+
 can 
limit the yield and purity of the desired Eu
2+
-containing complexes. 
 
Figure 2.5 Structures of Eu
2+
-containing complexes 2.41–2.47, which were synthesized by 
the reduction of Eu
3+
. 
2.2.3 Metathesis of Eu
2+
 Complexes 
While the other synthetic methods involve redox reactions to obtain Eu
2+
, the 
metathesis approach makes use of Eu
2+
 halides and alkali metal-containing ligands as 
precursors to generate the desired Eu
2+
-containing complex. The metathesis reaction has 
been successful in preparing several Eu
2+
-containing complexes including the bimetallic 
Eu2(Ap*py)3I(THF), 2.48, where Ap*py is deprotonated 6-methylpyridin-2-yl-[6-(2,4,6-
triisopropylphenyl)pyridin-2-yl]amine;
59
 a monometallic Eu
2+
-containing trans-N,N’-
dimethyl-meso-octaethylporphyrinogen complex, 2.49;
60
 a Eu
2+
-containing benzamidinate 
complex Eu[PhC(NSi(CH3)3)(2,6-(i-Pr)2NC6H3)]2(THF)2, 2.50;
61
 a Eu
2+
 complex with 
olefin-substituted cyclopentadienyl ligands [C5(CH3)4Si(CH3)2CH2CH=CH2]2Eu, 2.51;
62
 
the bis(diphosphanylamido complex [{(Ph2P)2N}2Eu(THF)3], 2.52;
63
 a Eu
2+
 complex 
containing bis(phosphinimino)methanides ligands [{(CH3)3SiNPPh2)2CH}EuI(THF)]2, 
2.53;
64
 the aminotroponiminate complex of compostion [{(i-Pr)2ATI}Eu{N-
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(Si(CH3)2}(THF)2], 2.54, where (i-Pr)2ATI is N-isopropyl-2-
(isopropylamino)troponiminate;
65
 and a monometallic, heteroleptic [(DIP2pyr)Eu(THF)3], 
2.55, where DIP2pyr is 2,5-bis{N-2,6-diisopropylphenyl)iminomethyl}pyrrolyl (Figure 
2.6).
66 
Complexes 2.48–2.55 were prepared from the metathesis reaction of EuI2(THF)x, 
where labile THF, iodine, or both are displaced by the desired ligand. Complex 2.50 
exhibits cisoid and transoid isomers with respect to the position of coordinated THF.
61
 The 
bidentate diphospanylamides, (Ph2P)2N
–
, in complex 2.52 are η2 coordinated to the Eu2+ 
center through the phosphorous and nitrogen. The structure of the bimetallic Eu
2+
-
containing complex 2.53 displays the tridentate bis(phosphinimino)methanide ligands 
bound to Eu
2+
 via two nitrogen atoms and a methine carbon atom. Two of these ligands are 
coordinated to a Eu
2+ 
center to form a six membered metallacycle with a twist boat 
conformation.
64
 When complex 2.53 was treated with K{CH(PPh2NSi(CH3)2}, the six-
coordinate amido Eu
2+
-containing
 
complex [{(CH3)3SiNPPh2)2CH}Eu{(Ph2P)2N}(THF)], 
2.56, was obtained. As observed in 2.53, the methine carbon was coordinated to Eu
2+
 in 
2.56, and the reported Eu–C (methine carbon) bond lengths were 2.945 Å and 2.878 Å for 
complexes 2.53 and 2.56, respectively.
64
 In contrast to 2.53 where iodine bridged two Eu
2+
 
centers, complex 2.56 is monometallic with a nonbridging iodine atom and THF occupying 
the axial positions and the tridentate (DIP2pyr)
–
 ligand that is bound to Eu
2+
 through its 
three nitrogen atoms affording a distorted pentagonal pyramidal complex. As an alternative 
to the metathesis reaction of EuI2(THF)x in preparing Eu
2+
-containing complexes, we used 
the commercially available EuI2 to prepare cryptates 2.10, 2.11, and 2.57–2.59.
25,58
 A 
similar europium halide salt was used to generate four-coordinate {Eu[(ArN)2CN(i-Pr)2]2}, 
2.60, where Ar is 2,6-diisopropylphenyl.
67
 Roesky and coworkers used a bimetallic Eu
2+
-
containing complex [{CH(PPh2NSiMe3)2}Eu(THF)(µ-I)]2 and NaBPh4 as precursors to 
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prepare [{CH(PPh2NSi(CH3)3)2}Eu(THF)3]BPh4, 2.61.
68
 The resulting complex was used 
to prepare other Eu
2+
-containing complexes via metathesis of the labile borate ligand.
68
 
Another example of a borate-containing Eu
2+
 complex [Cp*(µ-η6:η1-Ph)2EuBPh2], 62, was 
prepared from Eu(Cp*)2 in the presence of [Et3NH][BPh4]. The structural motif of 
complex 2.62 features one coordinated Cp* and two of the phenyl rings of BPh4
–
 ligand 
showing a µ-η6:η1 binding mode, with the ligands arranged in a pyramidal geometry 
around the coordination sphere of Eu
2+
. While density functional theory (DFT) calculations 
predicted a trigonal planar shape for complex 2.62, the large size of Eu
2+
 prefers 
intermolecular packing over intramolecular packing in the solid state, and agostic 
interactions may also have contributed to this deviation of geometry.
69
 In general, with the 
metathesis approach of preparing Eu
2+
-containing complexes, the presence of other 
oxidation states of Eu is not a problem as long as synthesis is performed under an inert 
atmosphere. The success of this third approach of metathesis relies on the completeness of 
the displacement of the alkali metal or a practical method of purification to remove 
byproduct salts. Steric limitations introduced by the incoming ligand may pose a problem 
in preparing the target Eu
2+
 complex. 
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Figure 2.6 Structures of Eu
2+
-containing complexes 2.48–2.62, which were obtained from 
the metathesis of Eu
2+
-containing complexes. 
Each of the three synthetic methods described here have distinct advantages and 
limitations, and each route must be carefully considered when choosing a method to 
synthesize a new complex. In addition, structural studies of the recently synthesized Eu
2+
-
containing complexes presented in this section demonstrate the rich coordination chemistry 
of Eu
2+
. Differences in the coordination environment in Eu
2+
-containing complexes can be 
attributed to steric and electronic effects of the coordinated ligands as well as the size and 
electronic properties of Eu
2+
 that is responsible, in part, to the agostic interaction observed 
in some Eu
2+
 complexes. 
The development of other Eu
2+
-containing complexes in conjunction with the use of 
other divalent lanthanides in generating complexes with Ln
2+–Ga+ or Ln2+–Al+ (Ln = Sm, 
Eu, Yb, or Tm) bonds is an active area of research.
70–72
 Their applications for use as 
reductants are currently being explored.
70 
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2.3 Applications of Eu2+-Containing Complexes 
The growing interest in Eu
2+
-containing complexes stems from the unique catalytic, 
photophysical, and magnetic properties of these complexes. The remainder of this review 
describes the use of Eu
2+
-containing complexes in four different applications. 
2.3.1 Reductants 
Eu
2+
 is a one-electron reductant for many systems. However, it was reported that a 
bimetallic Sm
2+
-containing complex has the potential to be a two-electron reductant per 
molecule.
73
 This discovery led to the pursuit of divalent lanthanide species, including Eu
2+
-
containing complexes, that could act as multielectron reductants. This active area of 
research is important in establishing a more complete understanding in the reduction 
chemistry of Eu
2+
. Lee and coworkers reported a Eu
2+
-containing complex 2.50 that serves 
as a one-electron reductant to a diphenyl dichalcogenide PhSeSePh to produce 
{Eu([PhC(NSi(CH3)3)(2,6-(i-Pr)2NC6H3)])2(µ-SePh2)}2, 2.63, in which the two Eu
3+
 
centers are bridged by diphenyl diselenides (Figure 2.7).
61
 Each Eu
3+
 ion in 2.63 assumed 
a distorted octahedral geometry and was coordinated by two η2-bound benzamidinate 
ligands. However, when the same Eu
2+
-containing bisamidinate complex was allowed to 
react with diphenyl ditellurides and iodine, both reactions were unsuccessful, indicating 
that the reducing strength of Eu
2+
 was not sufficient to reduce diphenyl ditellurides and 
iodine.
61
 Also, in the case of the macrocylic ligand system trans-N,N’-dimethyl-meso-
octaethylporphyrinogen, the Eu
2+
-containing complex cannot reduce t-butyl-1,4-diazabuta-
1,3-diene (t-Bu-DAB).
60
 However, the analogous Sm
2+
 complex forms a bimetallic 
complex when reacted with t-Bu-DAB.
60
 The formation of the bimetallic Sm
3+
 complex 
bridged by the reduced [t-Bu-DAB]
2–
 is driven by the reducing power of Sm
2+ 
towards t-
Bu-DAB, but the steric constraints due to the bulky t-butyl moieties makes this reaction 
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reversible.
60
 Because Eu
2+
 has a more positive Ln
2+
/Ln
3+
 oxidation potential (–0.35 V vs 
NHE) than Sm
2+ 
(–1.55 V vs NHE), the driving force to form an analogous bimetallic Eu3+ 
complex is hindered, presumably because the reducing strength of Eu
2+
 is not sufficient to 
reduce t-Bu-DAB. These examples of controlled redox potential could be useful in 
selective reductions during multistep syntheses and for developing the first Eu
2+
-containing 
complex that could act as multielectron reductant. 
 
Figure 2.7 Structure of Eu
2+
-containing reductant 2.63. 
An important factor that can control the reducing properties of Eu
2+
 is the nature of the 
ligands. As an example, the reaction with Cp*2Eu(OEt2) with C6F5-substituted 
diazabutadiene (DADC6F5)
–
 led to the oxidation of Eu
2+
 and formation of the radical anion 
(DADC6F5)
•–
.
74
 The presence of Eu
3+
 in the resulting complex was characterized by 
crystallographic data, magnetic susceptibility measurements, and IR spectroscopy. The 
electron-withdrawing characteristic of the C6F5 moiety and its proximity to the metal 
center is likely the cause of the facile oxidation of Eu
2+
. On the other hand, neither 
oxidation of Eu
2+ 
nor formation of radical anion was observed when t-butyl-substituted 
diazabutadiene was used.
74
 In general, the diazabutadienyl ligand can have rich redox 
chemistry when coupled with Eu
2+
 by modifying this ligand using substituents of different 
electronic properties. 
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2.3.2 Polymerization Initiators 
As discussed in the previous section, ligands can influence the rich reduction chemistry 
of Eu
2+
 where the resulting complex can play an important role in several applications 
including polymer chemistry. In the preparation of polymers, Eu
2+
-containing complexes 
can act as electron-transfer agents to initiate several polymerization processes. An example 
of this application is the activity of several Eu
2+
-containing complexes that contain indenyl 
ligands in the initiation of the polymerization of methyl methacrylate (MMA) and ε-
caprolactone.
11,12
 
2.3.2.1 Methyl Methacrylate Polymerization 
Eu
2+
-containing complexes 2.64–2.73 that contain functionalized indenyl ligands are 
used in the polymerization of MMA (Figure 2.8).
11,75–77
 The activity of these complexes in 
polymerizations and the stereochemistries of the resulting polymers are dependent on 
temperature and solvent (Figure 2.7). High activity is observed at low temperatures (–30 
to –60 °C for complexes 2.64 and 2.65; 0 to –60 °C for complexes 2.66–2.69, 2.72, and 
2.73; –30 to –45 °C for complexes 2.70 and 2.71), and these complexes have solvent-
dependent activities. Complexes 2.64, 2.65, and 2.72 have high activities when THF or 
dimethoxyethane is used as solvent instead of toluene. Complex 2.66 has high activity in 
dimethoxyethane, THF, and toluene; 2.67 show good activity in THF; and complexes 2.68, 
2.69, and 2.73 have high activity in dimethoxyethane. The molecular weights of the 
resulting MMA polymers were high (up to 443 kDa) at low temperatures indicating that 
chain propagation is favored at low temperatures.
11,75–77
 The mechanism of MMA 
polymerization was postulated to initiate through reductive dimerization of MMA via 
electron transfer from Eu
2+
, resulting in the formation of Eu
3+
 enolates.
11,75–77
 Propagation 
37 
 
did not go through an insertion mechanism because the indenyl ligand was not detected on 
the polymer chains by 
1
H NMR spectroscopy.
11,76
  
 
Figure 2.8 Structure of Eu
2+
-containing complexes 2.64–2.82, which were used as 
polymerization initiators. 
The stereochemistry of the MMA polymers is determined by 
1
H NMR spectroscopy. 
The majority of the MMA polymers produced using Eu
2+
-containing functionalized 
indenyl complexes 2.64, 2.65, 2.72 and 2.73 as initiators is syndiotactic.
11,77
 However, 
when complexes 2.66–2.68 were used in dimethoxethane or THF, a 1:1:1 ratio of isotactic, 
syndiotactic, and atactic polymers was obtained. But, predominantly syndiotactic polymers 
was obtained using 2.66 in toluene, and a decrease in the ratio of syndiotactic to isotactic 
polymers was observed using 2.70 when the solvent was changed from THF or 
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dimethoxyethane to toluene suggesting a solvent effect influences the stereochemistry of 
these polymers. The presence of several tacticities in the synthesized polymers was 
attributed to the rac/meso interconversion, which is favored by solvents including THF and 
dimethoxyethane.
77
 While the stereochemistry of the polymers showed solvent 
dependency, it is still unclear if this stereoregularity is influenced by the nature of the 
initiator, specifically on the metal and ligands. A similar study that uses different initiators 
(for example, different divalent lanthanide metal ions or a ligand system other than indene 
compounds) could answer this question. 
2.3.2.2 Ring-Opening Polymerization of ε-Caprolactone 
Eu
2+
-containing complexes 2.74–2.79 that contain indenyl, fluorenyl, and 
iminopyrrolyl ligands showed catalytic activity in the ring-opening polymerization of ε- 
caprolactone.
12,78–80
 With these catalysts, high activity is observed at high temperatures (0 
to 30 °C for complexes 2.75 and 2.76; –30 to 60 °C for complex 2.74; 0 to 60 °C for 
complex 2.77; and 30 to 60 °C for complexes 2.78 and 2.79), and the activities of these 
complexes depend on solvent. Complexes 2.77–2.79 have high activities when THF or 
toluene is the solvent; complex 2.74 exhibits high activity in dimethoxyethane, THF, and 
toluene; and 2.75 and 2.76 show good activity in toluene. Furthermore, the steric bulk of 
the substituents in the ligands may have an effect on the activity of the complexes and the 
molecular weights of the resulting polymers. When the silyl substituent in the furfuryl- or 
tetrahydrofurfuryl-functionalized indenyl ligands of complexes 2.75 and 2.76 was absent, 
no activity using the two complexes was observed. However, it is not clear what the role of 
the silyl substituent is in the polymerization process.
78
 The use of more sterically bulky 
ligands in 2.79 relative to the ligands in 2.78 has been implicated to affect the chain 
propagation process, thus affecting the molecular weights of the polymers.
80
 Wang and 
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coworkers proposed that the polymerization of ε-caprolactone is initiated by the formation 
of Eu
3+
-containing alkoxyl radical species formed from the oxidation of the Eu
2+
 metal 
center (Scheme 2.2).
12
 The alkoxyl radical species is believed to take a second Eu
2+
-
containing complex and produce a bimetallic Eu
3+
-containing complex that is bridged by 
the opened caprolactone.
12
 Subsequently, chain propagation occurs when subsequent 
molecules of ε-caprolactone are added to the Eu3+ complex via a coordination–insertion 
process.
12
  
Scheme 2.2 Proposed mechanism of polymerization of ε-caprolactone.12 Ind is the indenyl 
ligand. Adapted with permission from S. Zhou, S. Wang, E. Sheng, L. Zhang, Z. Yu, X. 
Xi, G. Chen, W. Luo, Y. Li. Eur. J. Inorg. Chem. 2007, 1519–1528. Copyright 2007 John 
Wiley and Sons. 
 
 
 
 
 
Because the role of the ligands on the polymerization of MMA and ε-caprolactone has 
yet to be elucidated, several Eu
2+
 complexes {η5:η1-[1-(CH3)3Si-3-(C5H9OCH2)C9H5]}2Eu, 
2.80;
81
 (η5:η1-C5H9OCH2C13H8)2Eu, 2.81;
82
 and (η5:η1-C5H10NCH2CH2C13H8)2Eu, 2.82,
82
 
containing functionalized indenyl and fluorenyl ligands were investigated in terms of their 
activity towards MMA and ε-caprolactone polymerization. The silyl substituent in the 
indenyl ligands in complex 2.80 is likely a key factor in the two polymerization 
processes.
81
 Without the silyl substituent in 2.80, no activity was observed for any reaction 
condition.
81
 However, high activity was observed for 2.80 for both MMA and ε-
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caprolactone polymerizations. The effect of the ligand is also evident in the case of 
complexes 2.81 and 2.82. Complex 2.81 with N-piperidineethyl functionalized fluorenyl 
ligands has higher activity in ε-caprolactone polymerization than complex 2.81 with 
tetrahydro-2H-pyranyl ligands under the same reaction conditions. However, this ligand 
effect was not observed on the polymerization of MMA. 
In general, Eu
2+
-containing complexes using fluorenyl ligands are more effective as 
catalysts for both MMA and ε-caprolactone polymerizations than indenyl ligands with 
similar substituents. While Eu
2+
-containing complexes 2.64–2.82 initiate the 
polymerization of MMA or ε-caprolactone, it would be useful to investigate the 
mechanistic role of the different ligands in initiation. Also, exploration of a broader ligand 
system would enable an in depth understanding of how to better control the properties of 
the synthesized polymers. Although a Eu
2+
 complex has been used in the 
cyclotrimerization of isocyanates, the scope of the ligands used is still limited.
83
 These 
ligand-centered studies would expand our understanding of the reduction chemistry of Eu
2+
 
and its application to synthetic and polymer chemistry. 
 2.3.3 Luminescent Complexes 
Aside from the rich reduction properties of Eu
2+
, this ion produces complexes that are 
luminescent both in solution and in the solid state. Current research efforts are directed 
towards developing Eu
2+
-containing complexes that have high luminescence efficiency.  
The luminescence of uncomplexed Eu
2+
 and Eu
3+
 in protic solvents is quenched by O–
H oscillators of coordinated solvent molecules.
84
 Thus, macrocyclic ligands including 
crown ethers and cryptands are used to encapsulate Eu
2+
, protecting this ion from 
luminescence quenching by solvent molecules. The luminescence properties of Eu
2+
-
containing crown ethers, azacrown ethers, cryptands, and polymers were reviewed by 
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Adachi and coworkers in 1998.
6
 Since then, efforts have focused on developing 
luminescent complexes with high quantum yields by introducing functional groups into 
macrocyclic ethers or by using other ligands that better encapsulate Eu
2+
.
85–88
 There is also 
a growing interest in the comparison of spectroscopic properties of Eu
2+
 in the solid state 
to Eu
2+
-containing complexes in solution. 
A variety of functional groups have been used to study the contribution of antenna 
effects and conjugated π systems on the luminescence efficiency of Eu2+-containing 
complexes.
86–87
 Pyridine groups, known for exhibiting an antenna effect in Eu
3+
-containing 
complexes, were introduced into 18-crown-6. When bis-pyridino-18-crown-6 was 
complexed with Eu
2+
, the emission of the complex in the solid state was quenched at room 
temperature, and only a weak emission at 430 nm was observed at 77 K, which is typical 
for Eu
2+
-containing crown ethers.
86
 This quenching is likely due to the energy transfer 
from the excited state quasi-5d energy level of Eu
2+
 to the π* levels of pyridine, and this 
quenching is not observed when unfunctionalized 18-crown-6, 2.83, was used.
86
 However, 
a blue luminescence was observed when benzo-15-crown-5, 2.84, and benzo-18-crown-6, 
85, were used as ligands.
54,87
 The Eu
2+
-containing complex with benzo-15-crown-5 is 
characterized by a Eu
2+ 
metal center that is sandwiched by two benzo-15-crown-5 
ligands.
86
 In the solid state, Eu
2+–2.85 shows an emission peak that is similar to what is 
observed in methanol at room temperature. This observation is also true for Eu
2+
-
containing 15-crown-5, Eu–2.86. These observations suggest that similar structures exist in 
the solid state and in solution.
88
 The mean lifetime of the excited state of Eu
2+–2.84 at 
room temperature is 0.65 µs in the solid state and 0.14 µs in methanol (Table 2.1).
87
 This 
difference in excited state lifetime is likely due to the additional relaxation processes 
caused by the methanolic O–H oscillators.87 Furthermore, a phenyl moiety in the crown 
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ether might contribute to a reduction in the lifetime because this moiety could rigidify the 
crown ether and lead to structural changes making Eu
2+
 more exposed to luminescence 
quenchers relative to unmodified crown ethers.
6
 Also, the cavity size of the crown ether 
affects the luminescence lifetime of the excited state. Among the three crown ethers 
studied, the cavity size of 2.86 is most efficient at reducing the number of coordinating 
anions or solvent molecules that decrease luminescence lifetime.
88
 
Table 2.1 Luminescence properties of Eu
2+
-containing complexes in methanol solution 
and in the solid state (room temperature and 77 K).
6,54,87,88 
Complex Maximum emission 
band, nm (solid) 
Maximum emission 
band, nm 
(methanol) 
Luminescence 
lifetime, µs 
(solid) 
Luminescence 
lifetime, µs 
(methanol) 
Eu
2+–2.83 ND (RT) 
411.5 (77 K) 
ND ND 
ND 
ND 
Eu
2+–2.84 422 (RT) 
427 (77 K) 
417 0.65 (RT) 
0.59 (77 K) 
0.14 
Eu
2+–2.85 425 (RT) 
430 (77 K) 
447 8.34 (RT) 
8.01 (77 K) 
0.028 
Eu
2+–2.86 433 (RT) 
417 (77 K) 
432 0.922 (RT) 
0.745 (77 K) 
0.800 
Legend: RT is room temperature, ND is no data available 
In general, macrocylic ligands with cavity sizes that closely match the ionic radius of 
Eu
2+
 are the best ligands to insulate Eu
2+
 from solvent-based luminescence quenchers. 
Rigidifying ligands by adding phenyl groups and the addition of substituents like pyridine, 
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leads to a decrease in luminescence emission. These factors should be taken into 
consideration when designing Eu
2+
-based luminescent materials. 
2.3.4 MRI Contrast Agents 
In addition to the reducing and luminescence properties of Eu
2+
, the magnetic 
properties of this ion are important in the development of Eu
2+
-based contrast agents for 
magnetic resonance imaging (MRI). In the last two decades, research on the properties of 
Eu
2+
 that are relevant to MRI has been reported. A fast water-exchange rate and an 
isoelectronic ground state to Gd
3+
 are properties that make Eu
2+
 an excellent candidate for 
use as a contrast agent for MRI.
89
 This area started when Merbach and coworkers reported 
the fast water-exchange rate of the Eu
2+
 aqua ion that is in the order of 10
9 
s
–1
. After 
detailed mechanistic studies on the water exchange of the Eu
2+
 aqua ion,
90
 investigations of 
the nuclear and electronic relaxation processes of Eu
2+ 
chelated by 
polyaminopolycarboxylates, commonly used with Gd
3+
, were performed.
91
 When chelated 
to diethylenetriamine pentaacetate (DTPA), Eu
2+
 has a water-exchange rate that is three 
orders of magnitude faster than the clinically approved contrast agent [GdDTPA]
2–
, 2.87, 
(Figure 2.9).
91
 In addition to water-exchange rate, other molecular parameters including 
rotational correlation time and electronic spin relaxation time are important factors that 
influence the efficiency of contrast agents, known as relaxivity. For example, despite the 
fast water-exchange of [EuDTPA]
3–
, 2.88, the reported relaxivity of 2.88 at 20 MHz is 
20% lower than that of 2.87 because relaxivity is influenced by fast rotation and by fast 
electronic spin relaxation.
91
 The same observation was implicated for the higher relaxivity 
of Eu
2+
-containing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate [EuDOTA]
2–
 
(4.74 mM
–1
s
–1
) than [EuDTPA]
3–
 (3.49 mM
–1
s
–1
) at 20 MHz and 298 K.
92
 Results with 
other Eu
2+
-containing complexes indicate that the unfavorable fast electronic spin 
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relaxation rate is not observed with all Eu
2+
 complexes.
91,93
 Tóth and coworkers reported 
that the electron paramagnetic resonance line widths of 2.10, are narrower by a factor of 8–
10 compared to 2.88, indicating a slower electronic spin relaxation of Eu
2+
 in cryptate 2.10 
relative to 2.88.
94
 Consequently, the observed electronic spin relaxation for Eu
2+
-
containing cryptates does not limit relaxivity. In addition to slow electronic spin relaxation, 
this Eu
2+
-containing cryptate has a fast water-exchange rate (10
8 
s
–1
) and contains two 
inner-sphere water molecules in a ten-coordinate complex.
94
 These properties are 
promising because they present an opportunity to develop Eu
2+
-containing cryptates as 
effective contrast agents for MRI. A review of the similarities and differences in terms of 
these molecular parameters for several Eu
2+
- and Gd
3+
-containing complexes and their 
implications to research on MRI contrast agents was written by Merbach and coworkers in 
2001.
93 
 
Figure 2.9 Structures of complexes 2.87 and 2.88.  
While Eu
2+
 has properties that make it a candidate for use as a contrast agent for MRI, 
its propensity to oxidize prevents in vivo applications.
57
 It was demonstrated in the work of 
Allen and coworkers that Eu
2+ 
can be oxidatively stabilized using coordination chemistry 
principles, including hard–soft acid–base theory, to the extent that it is more oxidatively 
stable than Fe
2+
 in hemoglobin.
57
 These studies raised the possibility of using Eu
2+
-
containing cryptates for in vivo applications. 
In addition to using modified cryptands as ligands to stabilize Eu
2+
, I investigated the 
relaxivity of several Eu
2+
-containing cryptates 2.10–2.11 at different field strengths (1.4, 3, 
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7, 9.4, and 11.7 T).
25,58
 These cryptates showed higher relaxivity at higher fields (7 and 9.4 
T) relative to lower fields (1.4 and 3 T) unlike common Gd
3+
-containing contrast 
agents.
25,58
 While high relaxivity is a requirement for effective contrast agents, other 
properties including kinetic stability need to be considered for utility in vivo. I 
demonstrated that Eu
2+
-containing cryptates 2.10 and 2.11 are stable to transmetallation in 
the presence of endogenous ions such as Ca
2+
, Mg
2+
, and Zn
2+
,
25 
and the Allen group is  
currently investigating the thermodynamic stability and toxicity of several other Eu
2+
-
containing cryptates. 
2.4 Conclusions 
The rapid increase in the number of Eu
2+
-containing complexes reported in the past 
few decades has paved the way to making these complexes commonplace in coordination 
chemistry. New information regarding the stability and utility of Eu
2+
-containing 
complexes using a variety of ligands has opened new frontiers in lanthanide chemistry. 
Careful control of ligand properties produces Eu
2+
-containing complexes that are useful in 
synthetic, materials, and medicinal applications. 
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3.1 Introduction 
Contrast-agent-enhanced magnetic resonance imaging (MRI) is a widely used, 
noninvasive imaging technique for clinical and preclinical research as well as diagnostic 
medicine. Most clinical imaging is performed at high field strengths (1.5 or 3 T); however, 
a shift to ultra-high field strength MRI (≥7 T) is desirable because of the increased signal-
to-noise ratio, spatial resolution, and shorter acquisition times enabled at these fields, 
which offer the potential to lead to early diagnoses of diseases and more accurate 
imaging in vivo.
1–4
 Consequently, preclinical research relies heavily on ultra-high field 
strengths. A major limitation is that common T1-reducing (positive) contrast agents at 
lower field strengths, such as Gd
III
-containing complexes, become inefficient at ultra-high 
field strengths.
2,5
 Multiple parameters—including the water-exchange rate, the number of 
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inner-sphere water molecules, the rotational correlation time, and the relaxation times of 
the electron spins of Gd
III—are in a complex interplay that is crucial to increasing 
relaxivity, r1, which is a measure of contrast-enhancing ability of a contrast agent.
2–4
 An 
alternative to Gd
III
 is Eu
II
, which is isoelectronic with Gd
III
 but has a faster water-exchange 
rate due to its lower charge density. However, until recently, research on Eu
II
 chemistry in 
aqueous solution was limited because of its tendency to oxidize to Eu
III
.
6–8
 Modified 
[2.2.2]cryptands were used to increase the oxidative stability of Eu
II
,
6
 and here, the 
molecular properties and imaging profiles of a series of Eu
II
-containing [2.2.2]cryptates 
(3.1–3.3 in Figure 3.1) that are, to the best of my knowledge, among a few reported 
contrast agents, and the first lanthanide-based contrast agents, that are more effective at 
ultra-high field strengths than at lower fields were reported.
9
  
 
Figure 3.1 Structures of GdDOTA (DOTA = 1,4,7,10-tetraazacyclododecane-
N,N’,N’’,N’’’-tetraacetate) and EuII-containing cryptates 3.1–3.3. Coordinated water 
molecules have been omitted for clarity.  
I hypothesized that Eu
II
-containing [2.2.2]cryptates in aqueous solution could be 
used as the basis for efficient positive contrast agents for ultra-high field strength MRI 
because Eu
II
 and Gd
III
 are isoelectronic but differ in other molecular parameters that 
influence relaxivity. This hypothesis is supported by studies of Eu
II
-containing complexes: 
for example, Eu
II
-containing [2.2.2]cryptate, 3.1, has been reported to have a fast water-
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exchange rate.
8
 The water-exchange rate of 3.1 is 3 × 10
8
 s
−1
, which is faster than most 
Gd
III
-based complexes and is very close to the optimal value (~10
8
 s
−1
 at 7 T) for 
developing efficient MRI contrast agents at ultra-high fields.
2,8
 Attempts to increase 
the water-exchange rate of Gd
III
-containing complexes have been made by altering the 
coordination number of ligands for Gd
III
 or by increasing steric bulk at the site where 
inner-sphere water binds.
10
 However, because of the complicated interplay between water-
exchange rate and other parameters that affect relaxivity, there is a need to simultaneously 
optimize all factors to increase the efficacy of contrast agents. In addition to its 
optimal water-exchange rate, 3.1 has two inner-sphere water molecules in a ten-coordinate 
complex, which should enable higher relaxivity than an equivalent complex with only one 
inner-sphere water molecule according to Solomon–Bloembergen–Morgan (SBM) theory. 
These favorable molecular properties prompted me to hypothesize that Eu
II
-containing 
cryptates would be candidates for contrast agents at ultra-high field MRI. 
To test my hypothesis, I investigated the imaging (longitudinal relaxivity, r1, at 3 
and 7 T) and physical (water-exchange rate, electron-spin relaxation rate, and number of 
inner-sphere water molecules) properties of a series of Eu
II
-containing [2.2.2]cryptates 
(Figure 3.1). Cryptands of 3.1 and 3.2 are commercially available, and I synthesized 
cryptate 3.3 (Scheme 3.1).  
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Scheme 3.1 Synthesis of biphenyl-based Eu
2+
-containing cryptate. 
 
3.2 Imaging Properties of Eu2+-Containing Cryptates 
3.2.1 Influence of Magnetic Field on Relaxivity 
Relaxivity was determined using multiple flip angles in gradient echo imaging 
experiments performed between 19 and 20 °C at 3 and 7 T (Table 3.1) and inversion 
recovery experiments at either 20 or 37 °C at 1.4 T.
11
 At all of these field strengths, Eu
II
-
containing cryptates 3.2 and 3.3 displayed higher r1 than clinically approved GdDOTA (up 
to 46, 71, and 92 higher at 1.4, 3, and 7 T, respectively). Furthermore, 
cryptate 3.1 displayed a higher relaxivity than GdDOTA at 7 T. I found that the r1 values 
of GdDOTA were not different at 3 and 7 T (Student t test). This result was expected based 
on what is known about fast rotating Gd
III
-containing complexes.
3
 However, Eu
II
-
containing complexes 3.1–3.3 showed an increase in r1 values at 7 relative to 3 T.
12
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Additionally, the r1 values of cryptates 3.1–3.3 increased as a function of molecular weight 
at all field strengths. These cryptates are two of a few examples of paramagnetic materials 
that demonstrate an increase in relaxivity at ultrahigh field strengths relative to lower field 
strengths.
13
 
Table 3.1 r1 values of GdDOTA and Eu
II
-containing cryptates 
 
r1 at 1.4 T  
(mM
–1
s
–1
)
 
T = 37 °C  
r1 at 3 T  
(mM
–1
s
–1
)
 
T = 19.8 °C
 
r1 at 7 T  
(mM
–1
s
–1
)
 
T = 19 °C
 
GdDOTA 3.00 ± 0.06 3.69 ± 0.06 3.73 ± 0.01 
3.1 2.09 ± 0.02 3.94 ± 0.12 5.01 ± 0.03 
3.2 3.67 ± 0.09 4.84 ± 0.08 6.47 ± 0.17 
3.3 4.39 ± 0.10 6.31 ± 0.07 7.17 ± 0.04 
All complexes were in phosphate buffered saline (PBS, pH = 7.4). Results are reported as 
mean ± standard error. 
To establish a more complete understanding of the behavior of the efficacy of these 
cryptates as a function of field strength, we measured the relaxivity of 3.1 and 3.2 at field 
strengths of 1.4, 3, 7, 9.4, and 11.7 T. These measurements allowed us to compare the 
efficiency of Eu
2+
-containing complexes at clinically relevant field strengths (1.4 and 3 T) 
with that at higher field strengths, which are commonly used in preclinical research (> 3 
T). Because relaxivity is dependent on temperature,
12b
 we compared field strengths at the 
same temperature. 
On comparing the efficacy of Eu
2+
-containing cryptates at field strengths of 3, 7, 
9.4, and 11.7 T (20 °C, pH = 7.4), the relaxivity of 3.2 is higher than that of 3.1 at all field 
strengths (Figure 3.2). This difference in relaxivity is likely due to the difference in 
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rotational correlation rate, which is the rate at which these molecules tumble in solution. 
This rate is proportional to the molecular weight for structurally similar compounds.
14
 The 
relaxivity of 3.1 increases from 3 to 7 T followed by a decrease above 9.4 T and that of Eu-
3.2 shows an increase in relaxivity from 3 to 7 T followed by a decrease above 7 T. This 
“bump” could be similar to the bump with a maximum value between 7 and 9.4 T observed 
at lower field strengths in the NMR dispersion plots of slowly rotating Gd
3+
-based contrast 
agents.
2
 An attempt to explain this increase in relaxivity at higher fields was made using a 
simulation of the Solomon–Bloembergen–Morgan (SBM) equations. Although the 
relaxivity values from this simulation matched the trend observed for GdDOTA, they did 
not fit the experimental data for Eu
2+
-containing complexes. The results of this simulation 
indicate that SBM theory alone cannot explain our observations. 
 
Figure 3.2 Proton longitudinal relaxivity (T = 20 °C, pH = 7.4) of GdDOTA (○) and Eu2+-
containing cryptates 3.1 (◊) and 3.2 (□) as a function of magnetic field strength. Error bars 
represent standard error of the mean. 
At a higher temperature (T = 37 °C, pH = 7.4, Figure 3.3), 3.1 displays an increase 
in relaxivity from 1.4 to 7 T and a decrease above 9.4 T. However, at 37 °C, the relaxivity 
of 3.2 at 1.4 and 9.4 T is the same. At all field strengths and temperatures measured 
(except 1.4 T), 3.1and 3.2 have higher relaxivities than GdDOTA. To further explain the 
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influence of temperature on the relaxivity of 3.1 and 3.2, I measured relaxivity as a 
function of temperature at constant field strength. 
 
Figure 3.3 Proton longitudinal relaxivity (T = 37 °C, pH = 7.4) of GdDOTA (○) and Eu2+-
containing cryptates 3.1 (◊) and 3.2 (□) as a function of magnetic field strength. Error bars 
represent standard error of the mean. 
3.2.2 Influence of Temperature on Relaxivity 
Temperature can have a dramatic influence on the relaxivity of contrast agents. To 
explore the temperature dependence of the relaxivity of 3.1 and 3.2, I measured the 
relaxivity at 15, 20, 30, 37, and 50 °C at 9.4 and 11.7 T at pH = 7.4 (Figures 3.4 and 3.5). 
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Figure 3.4 Proton longitudinal relaxivity (9.4 T and pH = 7.4) of Eu
2+
-containing cryptates 
3.1 (□) and 3.2 (○) as a function of temperature. Error bars represent standard error of the 
mean. 
 
Figure 3.5 Proton longitudinal relaxivity (11.7 T, pH = 7.4) of Eu
2+
-containing cryptates 
3.1 (□) and 3.2 (○) as a function of temperature. Error bars represent standard error of the 
mean. 
Another temperature-dependent parameter that contributes to relaxivity is water-
exchange rate, which is important when it approaches the magnitude of the relaxation rate 
of the bound water. When this happens, the plot of relaxivity versus temperature should 
show a plateau or a positive slope in the low temperature region. This case was not 
observed for either 3.1 or 3.2, implying that the water-exchange rates of 3.1 and 3.2 are 
fast enough to not limit relaxivity even at low temperatures. This conclusion is supported 
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by the results of variable temperature 
17
O NMR studies, which revealed that crypates 3.1 
and 3.2 have water-exchange rates of 3.3 × 10
8
 s
–1
 and 0.85 × 10
8
 s
–1
, respectively.
 
In 
general, the variation in the relaxivities of these cryptates with temperature is likely due to 
the changes in the rotational correlation rate of the complexes as temperature changes, 
similar to what is observed with Gd
3+
-containing complexes. 
 
3.2.3 Influence of pH on Relaxivity 
The effect of pH on the relaxivity of Eu
2+
-containing cryptates as contrast agents was 
examined as a gauge of their performance in vivo and to explore the potential of these 
complexes to behave as pH responsive agents (Figure 3.6). 
At 7 T and 19 °C, the relaxivity of 3.1 did not change significantly at any of the pH 
values measured from 3 to 10 (p = 0.01). The relaxivity of 3.2 exhibited the same behavior. 
These observations are expected for complexes that do not have functional groups that are 
sensitive to pH changes. Also, at 1.4 T and 37 °C, the relaxivity of 3.1 is independent of 
pH value (p = 0.01).  However, the relaxivity of 3.2 remained constant below pH 7.4, but 
between pH values of 7.4 and 8, the relaxivity of 3.2 decreased by 22% (from 3.67 ± 0.09 
to 2.86 ± 0.02 mM
–1
s
–1
) and remained constant above pH 8. In summary, the experiments 
at different pH values for 3.1 and 3.2 under two different sets of conditions (7 T at 19 °C 
and 1.4 T at 37 °C) indicate that the relaxivity of these cryptates is not influenced by pH 
over a physiologically relevant range. 
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Figure 3.6 Longitudinal relaxivity at 1.4 T at 37 °C (3.1 (■) and 3.2 (●)) and 7 T at 19 °C 
(3.1 (□) and 3.2 (○)) as a function of pH. Error bars represent standard error of the mean. 
3.2.4 Phantom Imaging Experiments 
To demonstrate the consequence of having higher relaxivity, I obtained phantom 
images (images of solutions) of GdDOTA and Eu
II
-containing complexes 3.1–3.3 using T1-
weighted imaging at 7 T (Figure 3.7). The MR images of Eu
II
 cryptates 3.1–3.3 showed 
higher signal intensity relative to PBS. This observation is indicative that Eu
II
 cryptates are 
effective at influencing the relaxation of water protons in solution. The signal intensities of 
the Eu
II
 complexes are different from each other (Student t test) with 3.3 giving rise to the 
highest signal intensity. The 1/T1 values were between 29 and 89% higher for 
cryptates 3.1–3.3 relative to GdDOTA. An increase in 1/T1 corresponds to higher signal 
intensity and, therefore, is advantageous for imaging. These imaging experiments 
demonstrate that cryptates 3.1–3.3 are effective contrast agents at ultra-high field strengths. 
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Figure 3.7 (a) T1-weighted MR images of solutions of PBS, GdDOTA (1.0 mM in PBS), 
and 3.1–3.3 (1.0 mM in PBS) at 7 T. The diameter of the tubes that were used for imaging 
was 6 mm. Imaging parameters were TR = 21 ms; TE = 3.26 ms; and resolution = 0.27 × 
0.27 × 2 mm
3
. (b) Comparison of 1/T1 values of the samples from (a) at 7 T. Error bars 
represent standard error of the mean. 
3.3 Physical Properties of Eu2+-Containing Cryptates 
3.3.1 Variable-Temperature 
17
O NMR Spectroscopy 
To understand the observations of r1 values, I used variable temperature 
17
O NMR 
spectroscopy to determine the molecular parameters expected to influence relaxivity 
(Table 3.2): the residence lifetime of bound water molecules, τm
298
, where water-exchange 
rate, kex
298
, is equal to 1/τm
298
; the longitudinal electronic relaxation time, T1e
298
; and the 
number of inner-sphere water molecules, q. To attain the highest relaxivity at ultra-high 
field strengths, water-exchange rate must be ~10
8
 s
−1
.
2
 The water-exchange rates of the 
Eu
II
 complexes are 6–94 times faster than GdDOTA and, consequently, are closer to being 
optimal at ultra-high field strengths as described by SBM theory. However, our 
observed water-exchange rate does not limit the relaxation enhancement for fast rotating 
complexes even at ultra-high fields. As seen from the data in Tables 3.1 and 3.2, r1 values 
  PBS  GdDOTA       3.1             3.2           3.3 
  PBS  GdDOTA       3.1             3.2           3.3 
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were larger for cryptates 3.2 and 3.3 relative to 3.1 despite 3.2 and 3.3 having 
slower water-exchange rates than 3.1. The differences in water-exchange rates among 3.1, 
3.2, and 3.3 could be attributed to the flexibility of the cryptates because having a flexible 
structure may lead to changes in steric bulk at the water-binding site thereby affecting 
water-exchange rate. The relaxivity differences among cyptates 3.1–3.3 are likely due to 
differences in molecular weight because increases in molecular weight correspond to 
decreases in rotational correlation rates for structurally similar monomeric complexes.
13
 
Table 3.2 Relaxivity parameters (based on 
17
O NMR and EPR data) and molecular 
weights of GdDOTA and cryptates 3.1–3.3. 
 GdDOTA 3.1
 
3.2 3.3
 
τm
298 
(ns) 287 ± 10 3.0 ± 0.4 11.7 ± 0.3 48 ± 4 
kex
298
 (10
8
 s
–1
) 0.035 3.3 0.85 0.21 
q 1 2 2 2 
T1e (ns) 29 120 41 1100 
g 1.9847 1.9774 1.9790 1.9786 
1/T2e (10
9
 s
–1
) 0.91 2.7 3.4 4.0 
τR
 
(ns)
a – 19.6 2.72 2.27 
MW (Da) 591 564 657 731 
a
 See Section 3.7 of this chapter for the method of estimating τR. 
 
SBM theory also describes the dependence of relaxivity on the electron spin relaxation, 
which we investigated with 
17
O NMR studies. Data acquired from variable temperature 
17
O 
NMR experiments were refitted using 63 unique values of T1e
298 
in the range of 10
−8–
10
−3
 s, and the T1e
298
 values that were associated with the best correlation coefficient are 
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reported in Table 3.2. The electron-spin relaxation rates of the Eu
II
 ion in cryptates 3.1–
3.3 were in the range of 10
6–107 s−1 and were not limiting as evidenced by the change in 
relaxivity with molecular weight. The differences in the obtained electronic relaxation rates 
among 3.1, 3.2, and 3.3 could be attributed to the symmetry differences among the 
cryptates. However, the influence of structural factors to correlation times that describe 
electronic spin relaxation is not yet fully understood.
15
 Another key parameter in 
increasing relaxivity at ultra-high fields is the number of inner-sphere water molecules. 
Eu
II
 cryptates have two inner-sphere water molecules, which corresponds to higher 
efficiency of a contrast agent relative to complexes with fewer inner-
sphere water molecules. In general, the superiority of the Eu
II
 cryptates over GdDOTA in 
enhancing relaxivity at ultra-high field strengths is likely due to a combination of factors. I 
have determined kex
298
, q, and T1e
298
 for cryptates 3.1–3.3 in an attempt to explain the 
molecular basis for our observations; however, the results cannot be satisfactorily 
interpreted using SBM theory. 
3.3.2 Electron Paramagnetic Resonance (EPR) Spectroscopy 
In addition to relaxivity and 
17
O NMR experiments, I also performed EPR experiments 
to investigate the electronic properties of these cryptates that include the g factor and the 
transverse electronic spin relaxation rate, 1/T2e, of the metal ion. The g factor values for all 
the complexes are almost close to 2 (Table 3.2). This value is expected for complexes of 
which the metal ion has an f
7
 electronic configuration.  
The EPR peak of Eu
2+
 shown in Figure 3.8 at X-band is likely to be a superposition of 
12 lines, which could become visible at higher frequencies (~225 GHz), as a result of 
coupling of Eu
2+
 isotopes, 
151
Eu
 
and
 153
Eu, with similar spin (I = 5/2) and natural 
abundance (47.82 and 52.18%, respectively).
16
 The presence of a shoulder in the EPR 
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profile could also be attributed to the presence of a mixture of species–a cryptate with one 
inner-sphere water molecule and a species with two coordinated water molecules. 
Comparing the X-band EPR profile of the unfunctionalized cryptate 3.1 to that of 
GdDOTA, the peak-to-peak linewidth in the EPR plot of cryptate 3.1 is wider  relative to 
that of GdDOTA (Figures 3.8 and 3.9). This translates to a faster electron spin relaxation 
for Eu
2+
 relative to Gd
3+
 as implied in Eq 3.1:  
Eq 3.1  
 
   
 
   √     
 
 
where β is the Bohr magneton constant, ΔHpp  is the peak-to-peak linewidth, and h is the 
Planck’s constant. Using the g factor, the transverse electron spin relaxation rate can be 
calculated, and looking at the 1/T2e values on Table 3.2, these cryptates have faster 
electronic spin relaxation rate (2.97–4.40 times  faster) than GdDOTA. 
 
Figure 3.8 X band EPR spectrum of cryptate 3.1 in PBS at 77 K. 
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Figure 3.9 X band EPR spectrum of GdDOTA in PBS at 77 K. 
3.4 Conclusions 
This study demonstrated that Eu
II
-based complexes 3.1–3.3 are effective contrast 
agents at ultra-high field strengths likely because of the interplay of water-exchange rate, 
rotational correlation rate, and the presence of two inner-sphere water molecules. To the 
best of our knowledge, these complexes are among a few reported examples of contrast 
agents that display increased r1 values at ultra-high field strengths relative to lower fields.  
Relaxometric studies of 3.1 and 3.2 showed that the efficiencies of these cryptates were 
higher at 7 and 9.4 T at 20 °C. Furthermore, the relaxivities of these complexes decreased 
as the temperature increased from 15 to 50 °C, likely due to the increase in rotational 
correlation rate with increasing temperature. In addition, the efficacy of 3.1 and 3.2 did not 
vary significantly in the pH range of 3–10, which suggests that these complexes are 
expected to display constant relaxivity in biologically relevant pH ranges. These studies 
lay the foundation for the use of Eu
2+
-containing cryptates as contrast agents for MRI. 
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3.5 Experimental Procedures 
3.5.1 Materials 
Commercially available chemicals were of reagent-grade purity or better and were used 
without further purification unless otherwise noted. Water was purified using a PURELAB 
Ultra Mk2 water purification system (ELGA). Dicholoromethane was dried using a solvent 
purification system (Vacuum Atmospheres Company) and degassed under vacuum. 
Triethylamine was distilled from CaH2 under an atmosphere of Ar.
17
 4-Allylbiphenyl was 
prepared according to a published procedure.
18
 Ozone was generated using an apparatus 
from Ozone Research and Equipment Corporation. For ozone generation, oxygen was 
passed through a column of anhydrous calcium sulfate before the ozone apparatus, and the 
oxygen flow rate and current were held constant at 1.0 L/min and 0.8 A, respectively. p-
Toluenesulfonyl chloride was recrystallized prior to use.
17 
 
Flash chromatography was performed using silica gel 60, 230–400 mesh (EMD 
Chemicals).
19
 Analytical thin-layer chromatography (TLC) was carried out on ASTM TLC 
plates precoated with silica gel 60 F254 (250 μm layer thickness). TLC visualization was 
accomplished using a UV lamp followed by charring with potassium permanganate stain 
(2 g KMnO4, 20 g K2CO3, 5 mL 5% w/v aqueous NaOH, 300 mL H2O). 
 The following commercially available buffers were degassed and used in relaxometric 
experiments: glycine/HCl (pH = 3), acetate (pH = 5), PBS (pH = 7.4), 2-amino-2-
(hydroxymethyl)propane-1,3-diol (TRIS) (pH = 8), and glycine/NaOH (pH = 10). 
3.5.2 Characterization 
1
H NMR spectra were obtained using a Varian Unity 400 (400 MHz) spectrometer, and 
13
C NMR spectra were obtained using a Varian Unity 400 (101 MHz) spectrometer. 
Chemical shifts are reported relative to residual solvent signals (CD3OD: 
1
H:  3.30, 13C:  
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49.00; CD3CN: 
1
H:  1.94, 13C:  118.26 and 1.30). 1H NMR data are assumed to be first 
order, and the apparent multiplicity is reported as “s” = singlet, “m” = multiplet, and “brs” 
= broad singlet. Italicized elements are those that are responsible for the shifts. High-
resolution electrospray ionization mass spectra (HRESIMS) were obtained using an 
electrospray time-of-flight high-resolution Waters Micromass LCT Premier XE mass 
spectrometer.  
Samples for inductively coupled plasma mass spectrometry (ICP–MS) were diluted 
using aqueous 2% nitric acid. Standard solutions were prepared by serial dilution using Eu, 
Gd, and Sr standards (High-Purity Standards). ICP–MS measurements were conducted on 
a PE Sciex Elan 9000 ICP–MS instrument with a cross-flow nebulizer and Scott-type spray 
chamber.  
3.5.3 Imaging and Relaxometric Experiments 
Susceptibility weighted imaging (SWI) and Volumetric Interpolated Breath Hold 
Examination (VIBE) were performed at 3 (Siemens TRIO) and 7 (ClinScan) Tesla (T). The 
acquisition parameters for SWI were as follows: TR = 37 ms, TE = 5.68–31.18 ms, and 
resolution = 0.5 × 0.5 × 2 mm
3
 for 3 T; TR = 21 ms, TE = 3.26–15.44 ms, and resolution = 
0.27 × 0.27 × 2 mm
3
 for 7 T. Multiple flip angles (5, 10, 15, 20, 25, and 30°) were used in 
the SWI experiments to allow for the determination of longitudinal relaxation time, T1.
20
 
On the other hand, the parameters used for VIBE were as follows: TR = 5 ms, TE = 1.71 ms, 
and resolution = 0.27 × 0.27 × 2 mm
3
 for 7 T. MR images were processed using SPIN 
software (SVN Revision 1751). Matlab (7.12.0.635 R2011a) was used to generate effective 
transverse relaxation time, T2
*
, and corrected T1 maps. The T1 values from the corrected T1 
maps were plotted vs the concentration of Gd or Eu in the samples to calculate longitudinal 
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relaxivities, r1.  The Matlab codes for T2* and T1 (with T2* correction) maps are shown in 
Appendix A. 
Inverse recovery experiments were performed using Bruker minispec mq (1.4 T), a 
Varian Unity 400 (9.4 T) at 400 MHz, and Varian–500S (11.7 T) spectrometer using 
GdDOTA, 3.1, 3.2, and 3.3 as samples, which were dissolved in degassed phosphate 
buffered saline (PBS) solutions (pH = 7.4). All the T1 measurements were made at 37 °C. 
The relaxivity of the complexes were calculated from the slopes of the linear plots of 1/T1 
versus concentration.  
Longitudinal relaxation times, T1, were also measured using inverse recovery methods 
with a Varian Unity 400 (9.4 T) at 400 MHz and 15, 20, 30, 37, and 50 °C, and a Varian 
500S instrument (11.7 T) at 500 MHz and 15, 20, 30, 37, and 50 °C. 
Variable-temperature 
17
O NMR measurements of degassed solutions of GdDOTA (20 
mM); 3.1 (5.0 mM); 3.2 (0.50 mM); 3.3 (0.42 mM), and their Sr
II
 analogues of 3.1 (5.0 
mM), 3.2 (0.50 mM), and 3.3 (0.42 mM) in phosphate buffered saline (PBS, pH = 7.4) as 
well as acidified water (HClO4, pH 3.4) were obtained on a Varian–500S (11.7 T) 
spectrometer. 
17
O-enriched water (10% H2
17
O, Cambridge Isotope Laboratories, Inc.) was 
added to samples to yield 1% 
17
O enrichment. Transverse and longitudinal 
17
O relaxation 
rates and chemical shifts were measured at 15, 20, 30, 40, 50, 60, and 70 °C. The Sr
II
 
analogues of 3.1, 3.2, 3.3, and the acidified water were used as diamagnetic references. 
A/ħ, q, and ΔE were fixed to –3.8 × 10–6 rad/s, 2, and 2.5 × 10–11 J/mol, respectively, for 
Eu
II
-containing cryptates. Data acquired from variable-temperature 
17
O NMR experiments 
were fitted using sixty unique values of T1e
298
 in the range of 10
–8–10–3 s, and the T1e
298 
values that were associated with the best correlation coefficients were reported. The least-
squares fits of the 
17
O NMR relaxation data were calculated using Origin software (8.0951 
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B951) following published procedures.
21 
The variable temperature 
17
O NMR data and fits 
are presented in Tables 3.3–3.6 and Figures 3.8–3.11. 
Table 3.3 
17
O NMR data for acidified water and GdDOTA. 
Temperature (°C) Linewidth (Hz) 
Acidified water GdDOTA 
70 33 97 
60 39 137 
50 50 197 
40 68 249 
30 99 281 
20 137 256 
15 160 241 
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Figure 3.10 
17
O NMR fits for GdDOTA. 
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Table 3.4 
17
O NMR data for Sr
II
 analog of 3.1 and cryptate 3.1. 
Temperature (°C) Linewidth (Hz) 
Sr analog of 3.1 3.1 
70 30 31 
60 34 37 
50 40 46 
40 53 57 
30 64 73 
20 91 111 
15 107 142 
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Figure 3.11 
17
O NMR fits for cryptate 3.1. 
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Table 3.5 
17
O NMR data for Sr
II
 analog of 3.2 and cryptate 3.2. 
Temperature (°C) Linewidth (Hz) 
Sr analog of 3.2 3.2 
70 30 37 
60 34 45 
50 41 57 
40 52 75 
30 71 105 
20 102 154 
15 126 183 
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Figure 3.12 
17
O NMR fits for cryptate 3.2. 
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Table 3.6 
17
O NMR data for Sr
II
 analog of 3.3 and cryptate 3.3. 
Temperature (°C) Linewidth (Hz) 
Sr analog of 3.3 3.3 
70 29 30 
60 33 35 
50 39 43 
40 48 55 
30 63 75 
20 90 108 
15 112 134 
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Figure 3.13 
17
O NMR fits for cryptate 3.3. 
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The T1e value for each complex corresponds to the T1e that gave the best correlation 
coefficient. A table is presented below that shows unique T1e values in the range 10
–8 
to  
10
–3 
s and their corresponding correlation coefficient for each of the four complexes when 
they were used in the fitting of the NMR data. The reported T1e values are shown in bold in 
the table. 
Table 3.7 T1e values for GdDOTA and cryptates 3.1–3.3 and the corresponding correlation 
coefficients (R
2
) in the 
17
O NMR fits. 
T1e
 
(s) Correlation coefficient (R
2
) 
GdDOTA 3.1 3.2 3.3 
1 × 10
–8 –8.51 0.91 0.67 –1.04 
2 × 10
–8
 0.69 0.95 0.99 –0.47 
3 × 10
–8
 0.98 0.96 0.99 –0.11 
4 × 10
–8
 0.70 0.96 1 0.12 
5 × 10
–8
 0.21 0.96 0.99 0.29 
6 × 10
–8 –0.33 0.96 0.99 0.42 
7 × 10
–8
 –0.87 0.96 0.99 0.51 
8 × 10
–8
 –1.37 0.96 0.99 0.58 
9 × 10
–8
 –1.83 0.96 0.99 0.64 
1 × 10
–7 –2.24 0.96 0.99 0.69 
2 × 10
–7
 –4.79 0.97 0.99 0.88 
3 × 10
–7
 –4.82 0.97 0.99 0.94 
4 × 10
–7
 –4.84 0.97 0.99 0.96 
5 × 10
–7
 –4.85 0.97 0.99 0.97 
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6 × 10
–7 –4.86 0.97 0.99 0.97 
7 × 10
–7
 –4.86 0.97 0.99 0.98 
8 × 10
–7
 –4.86 0.97 0.99 0.98 
9 × 10
–7
 –4.86 0.97 0.99 0.98 
1 × 10
–6 –4.87 0.97 0.99 0.98 
2 × 10
–6
 –4.87 0.97 0.99 0.99 
3 × 10
–6
 –4.87 0.97 0.99 0.99 
4 × 10
–6
 –4.87 0.97 0.99 0.99 
5 × 10
–6
 –4.87 0.97 0.99 0.99 
6 × 10
–6 –4.87 0.97 0.99 0.99 
7 × 10
–6
 –4.87 0.97 0.99 0.99 
8 × 10
–6
 –4.87 0.97 0.99 0.99 
9 × 10
–6
 –4.88 0.97 0.99 0.99 
1 × 10
–5 –4.88 0.97 0.99 0.99 
2 × 10
–5
 –4.88 0.97 0.99 0.99 
3 × 10
–5
 –4.88 0.97 0.99 0.99 
4 × 10
–5
 –4.88 0.97 0.99 0.99 
5 × 10
–5
 –4.88 0.97 0.99 0.99 
6 × 10
–5 –4.88 0.97 0.99 0.99 
7 × 10
–5
 –4.88 0.97 0.99 0.99 
8 × 10
–5
 –4.88 0.97 0.99 0.99 
9 × 10
–5
 –4.88 0.97 0.99 0.99 
1 × 10
–4 –4.88 0.97 0.99 0.99 
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2 × 10
–4
 –4.88 0.97 0.99 0.99 
3 × 10
–4
 –4.88 0.97 0.99 0.99 
4 × 10
–4
 –4.88 0.97 0.99 0.99 
5 × 10
–4
 –4.88 0.97 0.99 0.99 
6 × 10
–4 –4.88 0.97 0.99 0.99 
7 × 10
–4
 –4.88 0.97 0.99 0.99 
8 × 10
–4
 –4.88 0.97 0.99 0.99 
9 × 10
–4
 –4.88 0.97 0.99 0.99 
1 × 10
–3 –4.88 0.97 0.99 0.99 
2 × 10
–3
 –4.88 0.97 0.99 0.99 
3 × 10
–3
 –4.88 0.97 0.99 0.99 
4 × 10
–3
 –4.88 0.97 0.99 0.99 
5 × 10
–3
 –4.88 0.97 0.99 0.99 
6 × 10
–3 –4.88 0.97 0.99 0.99 
7 × 10
–3
 –4.88 0.97 0.99 0.99 
8 × 10
–3
 –4.88 0.97 0.99 0.99 
9 × 10
–3
 –4.88 0.97 0.99 0.99 
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Table 3.8 T1 data for GdDOTA (1.4 T, Temp = 37 °C).  
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 3.18 0.31 
0.5 1.69 0.59 
0.25 0.96 1.05 
0.125 0.58 1.71 
0.0625 0.40 2.51 
0 0.22 4.63 
 
 
 
 
 
 
 
 
 
Table 3.9 T1 data for Cryptate 3.1 (1.4 T, Temp = 37 °C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 3.13 0.32 
0.5 1.67 0.60 
0.25 0.93 1.07 
0.125 0.58 1.74 
0.0625 0.40 2.52 
0 0.22 4.63 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 3.33 0.30 
0.5 1.79 0.56 
0.25 1.00 1.00 
0.125 0.60 1.66 
0.0625 0.41 2.45 
0 0.22 4.63 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 2.30 0.43 
0.5 1.24 0.81 
0.25 0.73 1.37 
0.125 0.44 2.26 
0.0625 0.30 3.38 
0 0.22 4.63 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 2.31 0.43 
0.5 1.27 0.79 
0.25 0.65 1.54 
0.125 0.47 2.13 
0.0625 0.29 3.39 
0 0.22 4.63 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 2.31 0.43 
0.5 1.27 0.79 
0.25 0.65 1.54 
0.125 0.47 2.13 
0.0625 0.29 3.39 
0 0.22 4.63 
 
y = 2.9675x + 0.2136 
R² = 1 
0.00
2.00
4.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Gd Concentration (mM) 
 
y = 2.9147x + 0.2126 
R² = 1 
0.00
2.00
4.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Gd concentration (mM) 
 
y = 3.1195x + 0.2163 
R² = 1 
0.00
2.00
4.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Gd concentration (mM) 
 
y = 2.1239x + 0.1815 
R² = 0.9979 
0
1
2
3
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu Concentration (mM) 
 
y = 2.0506x + 0.1829 
R² = 0.9984 
0
1
2
3
0 0.5 1 1.5
1
/T
1
 (
S
-1
) 
Eu Concentration (mM) 
 
y = 2.1095x + 0.1897 
R² = 0.9995 
0
1
2
3
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu Concentration (mM) 
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Table 3.10 T1 data for Cryptate 3.2 (1.4 T, Temp = 37 °C).  
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 3.97 0.25 
0.5 2.13 0.47 
0.25 1.14 0.88 
0.125 0.69 1.46 
0.0625 0.45 2.21 
0 0.22 4.63 
 
 
 
 
 
 
 
 
 
 
Table 3.11 T1 data for Cryptate 3.3 (1.4 T, Temp = 37 °C). 
 
  
 
 
 
 
 
 
 
 
 
 
 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 3.96 0.25 
0.5 2.00 0.50 
0.25 1.15 0.87 
0.125 0.68 1.48 
0.0625 0.36 2.76 
0 0.22 4.63 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 3.69 0.27 
0.5 2.02 0.50 
0.25 1.11 0.90 
0.125 0.66 1.51 
0.0625 0.44 2.30 
0 0.22 4.63 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 4.57 0.22 
0.5 2.36 0.42 
0.25 1.25 0.80 
0.125 0.72 1.40 
0.0625 0.47 2.14 
0 0.22 4.63 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 4.77 0.21 
0.5 2.45 0.41 
0.25 1.33 0.75 
0.125 0.75 1.33 
0.0625 0.47 2.12 
0 0.22 4.63 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 4.41 0.23 
0.5 2.30 0.43 
0.25 1.23 0.81 
0.125 0.70 1.43 
0.0625 0.44 2.27 
0 0.22 4.63 
 
y = 3.7665x + 0.2155 
R² = 0.9999 
0
2
4
6
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu Concentration (mM) 
y = 2.9675x + 0.2136 
R² = 1 
0.00
2.00
4.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Gd Concentration (mM) 
 
y = 3.7594x + 0.1809 
R² = 0.9991 
0
2
4
6
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu Concentration (mM) 
 
y = 3.4831x + 0.2309 
R² = 0.9996 
0
1
2
3
4
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu Concentration (mM) 
 
y = 4.3686x + 0.186 
R² = 0.9998 
0
2
4
6
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu Concentration (mM) 
 
y = 4.5666x + 0.1898 
R² = 0.9999 
0
2
4
6
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu Concentration (mM) 
 
y = 4.2234x + 0.1867 
R² = 0.9999 
0
2
4
6
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu Concentration (mM) 
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Table 3.12 T1 data for GdDOTA (3 T, Temp = 19.8 °C).  
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 3.86 0.26 
0.5 1.88 0.53 
0.25 0.95 1.06 
0.125 0.53 1.90 
0.0625 0.45 2.24 
0 0.23 4.36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 3.98 0.25 
0.5 1.90 0.53 
0.25 1.07 0.93 
0.125 0.58 1.71 
0.0625 0.38 2.65 
0 0.21 4.78 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 3.97 0.25 
0.5 1.93 0.52 
0.25 1.05 0.95 
0.125 0.63 1.58 
0.0625 0.34 2.91 
0 0.22 4.62 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 3.73 0.27 
0.5 1.96 0.51 
0.25 1.02 0.98 
0.125 0.60 1.66 
0.0625 0.36 2.78 
0 0.24 4.19 
 
y = 3.6585x + 0.1338 
R² = 0.9955 
0.00
2.00
4.00
6.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Gd Concentration (mM) 
y = 2.9675x + 0.2136 
R² = 1 
0.00
2.00
4.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Gd Concentration (mM) 
 
y = 3.7873x + 0.1323 
R² = 0.9975 
0.00
2.00
4.
6.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Gd concentrat  ( ) 
 
y = 3.776x + 0.1366 
R² = 0.9979 
0.00
2.00
4.00
6.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Gd concentration (mM) 
 
y = 3.776x + 0.1366 
R² = 0.9979 
0.00
1.00
2.00
3.00
4.00
5.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Gd concentration (mM) 
y = 3.5511x + 0.1733 
R² = 0.9992 
1.00
2.00
3.00
4.00
1
/T
1
 (
s^
-1
) 
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Table 3.13 T1 data for Cryptate 3.1 (3 T, Temp = 19.8 °C).  
 
 
 
 
 
 
 
 
 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 4.10 0.24 
0.5 2.13 0.47 
0.25 1.07 0.93 
0.125 0.66 1.51 
0.0625 0.48 2.09 
0 0.22 4.62 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 3.88 0.26 
0.5 2.11 0.48 
0.25 1.10 0.91 
0.125 0.64 1.55 
0.0625 0.47 2.11 
0 0.23 4.36 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 4.44 0.23 
0.5 2.17 0.46 
0.25 1.18 0.85 
0.125 0.65 1.55 
0.0625 0.44 2.27 
0 0.21 4.78 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 4.17 0.24 
0.5 2.16 0.46 
0.25 1.08 0.92 
0.125 0.63 1.60 
0.0625 0.46 2.18 
0 0.24 4.19 
 
y = 3.9709x + 0.1742 
R² = 0.9987 
0.00
2.00
4.00
6.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
 
y = 4.2435x + 0.1438 
R² = 0.9985 
0.00
2.00
4.00
6.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
 
y = 3.6688x + 0.221 
R² = 0.9994 
0.00
2.00
4.00
6.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
 
y = 3.8898x + 0.1868 
R² = 0.9989 
0.00
2.00
4.00
6.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
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Table 3.14 T1 data for Cryptate 3.2 (3 T, Temp = 19.8 °C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 5.29 0.19 
0.5 2.34 0.43 
0.25 1.26 0.79 
0.125 0.74 1.35 
0.0625 0.48 2.07 
0 0.23 4.36 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 5.03 0.20 
0.5 2.46 0.41 
0.25 1.33 0.75 
0.125 0.72 1.38 
0.0625 0.45 2.22 
0 0.21 4.78 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 4.98 0.20 
0.5 2.56 0.39 
0.25 1.23 0.81 
0.125 0.73 1.38 
0.0625 0.41 2.42 
0 0.22 4.62 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 4.83 0.21 
0.5 2.48 0.40 
0.25 1.23 0.82 
0.125 0.68 1.48 
0.0625 0.48 2.08 
0 0.24 4.19 
 
y = 3.776x + 0.1366 
R² = 0.9979 
0.00
1.00
2.00
3.00
4.00
5.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Gd concentration (mM) 
 
y = 3.5511x + 0.1733 
R² = 0.9992 
0.00
2.00
3.00
4.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Gd concentration (mM) 
 
y = 5.0371x + 0.0987 
R² = 0.9927 
0.00
2.00
4.00
6.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
 
y = 4.8284x + 0.127
R² = 0.9988 
. 0
2. 0
4. 0
6. 0
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
 
y = 4.832x + 0.1405 
R² = 0.999 
0.00
2.00
4.00
6.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
 
y = 4.6489x + 0.1534 
R² = 0.9986 
0.00
2.00
4.00
6.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
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Table 3.15 T1 data for Cryptate 3.3 (3 T, Temp = 19.8 °C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 6.58 0.15 
0.5 3.05 0.33 
0.25 1.69 0.59 
0.125 0.86 1.16 
0.0625 0.60 1.68 
0 0.23 4.36 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 6.62 0.15 
0.5 3.07 0.33 
0.25 1.62 0.62 
0.125 0.85 1.17 
0.0625 0.54 1.85 
0 0.21 4.78 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 6.29 0.16 
0.5 3.24 0.31 
0.25 1.83 0.55 
0.125 0.83 1.20 
0.0625 0.53 1.90 
0 0.22 4.62 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 6.58 0.15 
0.5 3.06 0.33 
0.25 1.52 0.66 
0.125 0.83 1.20 
0.0625 0.52 1.93 
0 0.24 4.19 
 
y = 3.776x + 0.1366 
R² = 0.9979 
0.00
1.00
2.00
3.00
4.00
5.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Gd concentration (mM) 
 
y = 3.5511x + 0.1733 
R² = 0.9992 
0.00
2.00
3.00
4.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Gd concentration (mM) 
 
y = 6.3294x + 0.1245 
R² = 0.9967 
0.00
5.00
10.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
 
y = 6.1245x + 0.1777 
R² = 0.9989 
0. 0
5.00
10.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
 
y = 6.4163x + 0.0797 
R² = 0.9969 
0.00
5.00
10.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
 
y = 6.3816x + 0.0641 
R² = 0.9962 
0.00
5.00
10.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
87 
 
Table 3.16 T1 data for GdDOTA (7 T, Temp = 19 °C).  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 4.07 0.25 
0.5 2.16 0.46 
0.25 1.25 0.80 
0.125 0.70 1.42 
0.0625 0.46 2.20 
0 0.51 1.96 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 4.08 0.25 
0.5 2.19 0.46 
0.25 1.25 0.80 
0.125 0.70 1.43 
0.0625 0.46 2.18 
0 0.56 1.77 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 4.08 0.25 
0.5 2.19 0.46 
0.25 1.24 0.80 
0.125 0.70 1.43 
0.0625 0.45 2.20 
0 0.50 1.99 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 4.10 0.24 
0.5 2.22 0.45 
0.25 1.24 0.81 
0.125 0.71 1.42 
0.0625 0.46 2.17 
0 0.54 1.86 
 
y = 3.7106x + 0.3254 
R² = 0.9945 
0.00
2.00
4.00
6.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Gd concentration (mM) 
 
y = 3.7101x + 0.3426 
R² = 0.9923 
0.00
2.00
4.00
6.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Gd concentration (mM) 
 
y = 3.7403x + 0.3216 
R² = 0.9949 
0.00
2.00
4.00
6.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Gd concentration (mM) 
 
y = 3.7437x + 0.3335 
R² = 0.9936 
0.00
2.00
4.00
6.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Gd concentration (mM) 
88 
 
Table 3.17 T1 data for Cryptate 3.1 (7 T, Temp = 19 °C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 5.26 0.19 
0.5 2.96 0.34 
0.25 1.55 0.65 
0.125 0.87 1.15 
0.0625 0.55 1.83 
0 0.51 1.96 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 5.32 0.19 
0.5 3.15 0.32 
0.25 1.59 0.63 
0.125 0.89 1.13 
0.0625 0.57 1.77 
0 0.56 1.77 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 5.32 0.19 
0.5 3.15 0.32 
0.25 1.59 0.63 
0.125 0.89 1.13 
0.0625 0.57 1.77 
0 0.56 1.77 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 5.32 0.19 
0.5 3.15 0.32 
0.25 1.59 0.63 
0.125 0.89 1.13 
0.0625 0.57 1.77 
0 0.56 1.77 
 
y = 3.7403x + 0.3216 
R² = 0.9949 
0.00
2.00
4.00
6.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Gd concentration (mM) 
 
y = 4.9477x + 0.3517 
R² = 0.996 
0.00
2.00
4.00
6.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
 
y = 5.0095x + 0.3964 
R² = 0.9921 
0.00
2.00
4.00
6.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
 
y = 5.0524x + 0.2408 
R² = 0.9974 
0.00
2.00
4.00
6.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
 
y = 5.0337x + 0.3413 
R² = 0.995 
0.00
2.00
4.00
6.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
89 
 
Table 3.18 T1 data for Cryptate 3.2 (7 T, Temp = 19 °C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 7.14 0.14 
0.5 3.73 0.27 
0.25 2.10 0.48 
0.125 1.63 0.61 
0.0625 1.04 0.96 
0 0.51 1.96 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 7.58 0.13 
0.5 3.97 0.25 
0.25 2.18 0.46 
0.125 1.81 0.55 
0.0625 1.16 0.86 
0 0.56 1.77 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 6.67 0.15 
0.5 3.60 0.28 
0.25 2.01 0.50 
0.125 1.56 0.64 
0.0625 1.04 0.96 
0 0.50 1.99 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 7.09 0.14 
0.5 3.66 0.27 
0.25 2.11 0.48 
0.125 1.71 0.59 
0.0625 1.10 0.91 
0 0.54 1.86 
 
y = 3.776x + 0.1366 
R² = 0.9979 
0.00
1.00
2.00
3.00
4.00
5.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Gd concentration (mM) 
 
y = 3.5511x + 0.1733 
R² = 0.9992 
0.00
2.00
3.00
4.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Gd concentration (mM) 
 
y = 6.4889x + 0.5986 
R² = 0.997 
0.00
5.00
10.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
 
y = 6.1748x + 0.5055 
R² = 0.99 
0.00
5.00
10
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
 
y = 6.8392x + 0.6675 
R² = 0.9953 
0.00
5.00
10.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
 
y = 6.3695x + 0.644 
R² = 0.9953 
0.00
5.00
10.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
90 
 
Table 3.19 T1 data for Cryptate 3.3 (7 T, Temp = 19 °C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 7.58 0.13 
0.5 3.46 0.29 
0.25 1.78 0.56 
0.125 1.03 0.97 
0.0625 0.65 1.54 
0 0.51 1.96 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 7.63 0.13 
0.5 3.51 0.29 
0.25 1.79 0.56 
0.125 1.04 0.96 
0.0625 0.67 1.49 
0 0.56 1.77 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 7.58 0.13 
0.5 3.51 0.29 
0.25 1.79 0.56 
0.125 1.01 0.99 
0.0625 0.64 1.55 
0 0.50 1.99 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
1 7.46 0.13 
0.5 3.50 0.29 
0.25 1.77 0.56 
0.125 1.02 0.98 
0.0625 0.67 1.50 
0 0.54 1.86 
 
y = 7.1821x + 0.183 
R² = 0.9921 
0.00
5.00
10.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
 
y = 7.2167x + 0.2029 
R² = 0.9913 
0.00
5.00
10.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
 
y = 7.069x + 0.2102 
R² = 0.993 
0.00
5.00
10.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
 
y = 7.2076x + 0.1766 
R² = 0.993 
0.00
5.00
10.00
0 0.5 1 1.5
1
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
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Table 3.20 T1 data for GdDOTA (11.7 T, Temp = 37 °C).  
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
5 13.08 0.08 
2.5 6.89 0.15 
1.25 3.93 0.25 
0 3.01 0.33 
 
 
 
 
 
 
 
 
Table 3.21 T1 data for Cryptate 3.1 (11.7 T, Temp = 37 °C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
5 13.21 0.08 
2.5 7.10 0.14 
1.25 4.07 0.25 
0 3.01 0.33 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
5 13.24 0.08 
2.5 7.24 0.14 
1.25 3.62 0.28 
0 3.01 0.33 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
10 29.08 0.03 
5 13.28 0.08 
2.5 8.08 0.12 
0 3.01 0.33 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
10 28.54 0.04 
5 14.02 0.07 
2.5 7.97 0.13 
0 3.01 0.33 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
7.63 23.53 0.04 
3.825 11.21 0.09 
1.9125 6.52 0.15 
0 3.01 0.33 
 
y = 2.0968x + 2.1401 
R² = 0.9691 
0.00
10.00
20.00
0 2 4 61
/T
1
 (
s^
-1
) 
Gd concentration (mM) 
 
y = 2.1182x + 2.2134 
R² = 0.9746 
0.00
10.00
20.00
0 2 4 61
/T
1
 (
s^
-1
) 
Gd concentration (mM) 
 
y = 2.1582x + 2.0559 
R² = 0.9636 
0.00
10.00
20.00
0 2 4 61
/T
1
 (
s^
-1
) 
Gd concentration (mM) 
 
y = 2.6244x + 1.8831 
R² = 0.9862 
0.00
20.00
40.00
0 5 10 151
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
 
y = 2.7305x + 1.9453 
R² = 0.9855 
0.00
20.00
40.00
0 5 101
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
 
y = 2.5813x + 2.0913 
R² = 0.9931 
0.00
20.00
40.00
0 5 10 151
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
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Table 3.22 T1 data for Cryptate 3.2 (11.7 T, Temp = 37 °C).  
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
10 36.19 0.03 
5 17.03 0.06 
2.5 9.23 0.11 
0 3.01 0.33 
 
 
 
 
 
 
 
 
Table 3.23 T1 data for Cryptate 3.3 (11.7 T, Temp = 37 °C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
10 35.54 0.03 
5 18.34 0.05 
2.5 9.29 0.11 
0 3.01 0.33 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
7.63 27.93 0.04 
3.825 13.88 0.07 
1.9125 7.05 0.14 
0 3.01 0.33 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
13 63.86 0.02 
6.5 28.23 0.04 
3.25 14.52 0.07 
0 3.01 0.33 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
13 65.36 0.02 
6.5 29.06 0.03 
3.25 14.45 0.07 
0 3.01 0.33 
 
y = 3.3596x + 1.6698 
R² = 0.9913 
0.00
20.00
40.00
0 5 10 151
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
 
y = 3.3054x + 2.0834 
R² = 0.9963 
0.00
20.00
40.00
0 5 10 151
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
 
y = 3.3404x + 1.8072 
R² = 0.9898 
0.00
20.00
40.00
0 5 101
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
 
y = 4.7321x + 0.4932 
R² = 0.9901 
0.00
50.00
100.00
0 5 10 151
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
 
y = 4.8603x + 0.3274 
R² = 0.9902 
0.00
50.00
100.00
0 5 10 151
/T
1
 (
s^
-1
) 
Eu concentration (mM) 
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Table 3.24 T1 data for GdDOTA (11.7 T, Temp = 20 °C).  
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
5 16.89 0.06 
2.5 8.79 0.11 
1.25 4.73 0.21 
0 2.84 0.35 
 
 
 
 
 
 
 
 
Table 3.25 T1 data for Cryptate 3.1 (11.7 T, Temp = 20 °C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
5 16.83 0.06 
2.5 8.77 0.11 
1.25 4.72 0.21 
0 3.01 0.35 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
5 16.88 0.06 
2.5 8.77 0.11 
1.25 4.71 0.21 
0 3.01 0.35 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
10 41.19 0.02 
5 22.20 0.05 
2.5 10.90 0.09 
0 2.84 0.35 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
10 40.78 0.02 
5 18.47 0.05 
2.5 10.41 0.10 
0 3.01 0.35 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
7.63 34.89 0.03 
3.825 16.88 0.06 
1.9125 8.87 0.11 
0 3.01 0.35 
 
y = 2.8959x + 1.9774 
R² = 0.9839 
0.00
10.00
20.00
0 2 4 6
1
/T
1
 (
s^
-1
) 
Gd concentration (mM) 
 
y = 2.8814x + 1.9902 
R² = 0.9837 
0.00
10.00
20.00
0 2 4 6
1
/T
1
 (
s^
-1
) 
Gd concentration (mM) 
 
y = 2.8928x + 1.9776 
R² = 0.9834 
0.00
10.00
20.00
0 2 4 6
1
/T
1
 (
s^
-1
) 
Gd concentration (mM) 
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Table 3.26 T1 data for Cryptate 3.2 (11.7 T, Temp = 20 °C).  
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
10 49.70 0.02 
5 24.30 0.04 
2.5 12.57 0.08 
0 2.84 0.35 
 
 
 
 
 
 
 
 
 
Table 3.27 T1 data for Cryptate 3.3 (11.7 T, Temp = 20 °C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
10 50.10 0.02 
5 26.12 0.04 
2.5 12.70 0.08 
0 3.01 0.35 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
7.63 39.98 0.03 
3.825 19.83 0.05 
1.9125 10.40 0.10 
0 3.01 0.35 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
13 84.75 0.01 
6.5 39.64 0.03 
3.25 19.77 0.05 
0 2.84 0.35 
Concn 
(mM) 
1/T1  
(s
–1
) 
T1  
(s) 
13 84.82 0.01 
6.5 38.62 0.03 
3.25 20.01 0.05 
0 3.01 0.35 
 
y = 4.7305x + 1.6612 
R² = 0.9969 
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1
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y = 4.9201x + 1.8244 
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/T
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) 
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3.5.4 Synthesis 
Scheme 3.2 Synthetic route to cryptate 3.3. 
 
3-(Biphenyl-4-yl)propane-1,2-diol (3.4): To a mixture of 4-allylbiphenyl (4.00 g, 20.6 
mmol, 1 equiv), t-BuOH (150 mL), and H2O (150 mL) was added sequentially K3Fe(CN)6 
(20.3 g, 61.8 mmol, 3 equiv), K2CO3∙H2O (9.65 g, 61.8 mmol, 3 equiv), and a solution of 
OsO4 in t-BuOH (95.9 mM, 2.70 mL, 0.0129 equiv). The reaction mixture was stirred for 
20 h at ambient temperature at which point Na2SO3 (7.79 g, 61.8 mmol, 3 equiv) was 
added, and stirring was continued for 4 h. The resulting solution was concentrated to 
dryness under reduced pressure, and the residue was extracted with Et2O (6 × 50 mL). 
After removal of Et2O under reduced pressure, purification was performed using silica gel 
chromatography (1:1 hexanes/ethyl acetate) to yield 4.25 g (90%) of 3.4 as white solid. 
1
H 
NMR (400 MHz, CD3OD, ): 2.66–2.90 (m, CH2, 2H), 3.44–3.56 (m, CH2, 2H), 3.81–3.89 
(m, CH, 1H), 7.24–7.58 (m, CH, 9H); 13C NMR (101 MHz, CD3OD, ): 40.5 (CH2), 66.6 
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(CH2), 74.4 (CH), 127.80 (CH), 127.81 (CH), 128.1 (CH), 129.8 (CH), 130.9 (CH), 139.3, 
140.3, 142.2; TLC: Rf = 0.33 (1:1 hexanes/ethyl acetate); HRESIMS (m/z): [M + Na]
+
 
calcd for C15H16O2Na, 251.1048; found, 251.1046. 
4-(1,2-Bis(allyloxy)ethyl)biphenyl (3.5): To a solution of 3.4 (3.10 g, 13.5 mmol, 1 equiv) 
in anhydrous dimethoxyethane (60 mL) under Ar at ambient temperature was added NaH 
(2.53 g, 52.6 mmol, 4 equiv) followed by the dropwise addition of 1-bromoprop-2-ene 
(4.45 mL, 52.6 mmol, 4 equiv). The resulting reaction mixture was heated at reflux for 23 
h and allowed to cool to ambient temperature before excess NaH was quenched with 
methanol (2 mL). Solvent was removed under reduced pressure; the resulting residue was 
extracted with ethyl acetate (3 × 20 mL); and the combined ethyl acetate solutions were 
washed with water (3 × 20 mL). The organic phase was dried over Na2SO4 and 
concentrated under reduced pressure. Purification was performed using silica gel 
chromatography (9:1 hexanes/ethyl acetate) to yield 3.85 g (95%) of 3.5 as a yellow oil. 
1
H 
NMR (400 MHz, CD3CN, ): 2.79–2.91 (m, CH2, 2H), 3.37–3.48 (m, CH2, 2H), 3.68–3.76 
(m, CH, 1H), 3.93–4.11 (m, CH2, 4H), 5.04–5.32 (m, CH2, 4H), 5.78–5.98 (m, CH, 2H), 
7.28–7.66 (m, CH, 9H); 13C NMR (101 MHz, CD3CN, ): 38.1 (CH2), 72.3 (CH2), 72.6 
(CH2), 79.8 (CH), 116.4 (CH2), 116.7 (CH2), 127.6 (CH), 127.7 (CH), 128.1 (CH), 129.8 
(CH), 131.0 (CH), 136.2 (CH), 136.6 (CH),  139.2, 139.5, 141.6; TLC: Rf = 0.53 (9:1 
hexanes/ethyl acetate); HRESIMS (m/z): [M + Na]
+
 calcd for C21H24O2Na, 331.1674; 
found, 331.1669. 
2,2’-(Propane-1,2-diylbisoxy-3-biphenyl-4-yl)-diethanol (3.6):  Ozone was passed 
through a solution of 5 (4.00 g, 12.9 mmol, 1 equiv) in methanol (100 mL) at –50 °C until 
the starting compound was consumed (55 min). The resulting reaction mixture was purged 
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with Ar, and NaBH4 (4.87 g, 129 mmol, 10 equiv) was added. The mixture was stirred for 
1 h, a mixture of HOAc/H2O 1:10 (v/v) (18 mL) was added, and the resulting solution was 
stirred for 2 h. Volatile components were removed under reduced pressure, and the residue 
was extracted with ethyl acetate (6 × 20 mL). The extract was concentrated under reduced 
pressure, and purification was performed using silica gel chromatography (ethyl acetate) to 
yield  3.31 g (81%) of 3.6 as pale yellow oil. 
1
H NMR (400 MHz, CD3CN, ): 2.75–2.90 
(m, CH2, 2H), 3.01 (brs, OH, 2H), 3.25–3.77 (m, CH and CH2, 11H), 7.29–7.68 (m, CH, 
9H); 
13
C NMR (101 MHz, CD3CN, ): 38.1 (CH2), 61.9 (CH2), 62.2 (CH2), 72.3 (CH2), 
73.3 (CH2), 73.6 (CH2), 80.8 (CH), 127.6 (CH), 127.7 (CH), 128.2 (CH), 129.8 (CH), 
131.0 (CH), 139.1,  139.6, 141.6; TLC: Rf = 0.44 (ethyl acetate); HRESIMS (m/z): [M + 
H]
+
 calcd for C19H25O4, 317.1753; found, 317.1745. 
2,2’-(Propane-1,2-diylbisoxy-3-biphenyl-4-yl)-ditosylate (3.7):  A solution of tosyl 
chloride (3.71 g, 19.5 mmol, 3 equiv) in CH2Cl2 (22 mL) was added in a dropwise manner 
to an ice-cooled solution of 3.6 (2.06 g, 6.51 mmol, 1 equiv), triethylamine (5.45 mL, 39.1 
mmol, 6 equiv), and dimethylaminopyridine (0.030 mL, 0.25 mmol, 0.038 equiv) in 
CH2Cl2 (33 mL), and the resulting mixture was stirred for 24 h while warming to ambient 
temperature. The reaction mixture was washed sequentially with water (2 × 33 mL), 
saturated aqueous Na2CO3 (2 × 22 mL), and saturated aqueous citric acid (2 × 22 mL); 
dried over Na2SO4; and concentrated under reduced pressure. Purification was performed 
using silica gel chromatography (stepwise gradient of 3:1→1:1 hexanes/ethyl acetate) to 
yield 3.15 g (78%) of 3.7 as a light yellow oil. 
1
H NMR (400 MHz, CD3CN, ): 2.37 (s, 
CH3, 6H), 2.60–2.74 (m, CH2, 2H), 3.20–3.35 (m, CH2, 2H), 3.47–3.58–3.67 (m, CH and 
CH2, 5H), 3.97–4.12 (m, CH2, 4H), 7.18–7.81 (m, CH, 17H); 
13
C NMR (101 MHz, 
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CD3CN, ): 21.6 (CH3), 37.7 (CH2), 68.2 (CH2), 69.3 (CH2), 70.8 (CH2), 71.1 (CH2), 73.1 
(CH2), 80.7 (CH), 127.6 (CH), 127.7 (CH), 128.2 (CH), 128.7 (CH), 129.8 (CH), 131.0 
(CH), 133.8, 138.6, 139.5, 141.6, 146.3; TLC: Rf = 0.21 (3:1 hexanes/ethyl acetate); 
HRESIMS (m/z): [M + Na]
+
 calcd for C33H36O8S2Na, 647.1749; found, 647.1735. 
5-(Biphenyl-4-ylmethyl)-4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane 
(3.8): Under an atmosphere of Ar, 4,13-diaza-18-crown-6-ether (0.177 g, 0.675 mmol, 1 
equiv) was added to a suspension of Cs2CO3 (1.08 g, 3.33 mmol, 4.93 equiv) in anhydrous 
acetonitrile (37 mL). The mixture was heated to 60 °C, and a solution of 7 (0.478 g, 0.765, 
1.13 equiv) in anhydrous acetonitrile (13 mL) was added. The reaction mixture was heated 
at reflux for 115 h, cooled to ambient temperature, and filtered through celite. Solvent was 
removed under reduced pressure, and purification was performed using silica gel 
chromatography (stepwise gradient of 20:1→10:1 CH2Cl2/methanol) to yield 73.6 mg 
(21%) of 3.8 as a pale yellow oil. 
1
H NMR (400 MHz, CD3CN, ): 2.55–2.88 (m, 10H), 
3.03–3.11 (m, 1H), 3.32–3.82 (m, 26H),  7.30–7.66 (m, CH, 9H); 13C NMR (101 MHz, 
CD3CN, ): 38.4 (CH2), 53.4 (CH2), 53.5 (CH2), 53.7 (CH2), 53.8 (CH2), 54.1 (CH2), 54.3 
(CH2), 66.1 (CH2), 68.0 (CH2), 68.1 (CH2), 68.57 (CH2), 68.59 (CH2), 68.8 (CH2), 68.9 
(CH2), 69.2 (CH2), 69.6 (CH2), 71.4 (CH2),  79.4 (CH), 126.7 (CH), 127.7 (CH), 127.8 
(CH), 128.3 (CH), 129.2 (CH), 129.9 (CH), 131.0 (CH), 138.4,  139.6, 141.5; TLC: Rf = 
0.23 (10:1 CH2Cl2/methanol); HRESIMS (m/z): [M + H]
+
 calcd for C31H47O6N2, 543.3434; 
found, 543.3425. 
General Procedure for the synthesis of Eu
II
-containing cryptates (3.1–3.3): A degassed 
aqueous solution of EuCl2 (1 equiv) was mixed with a degassed aqueous solution of a 
cryptand (2 equiv). The resulting mixture was stirred for 12 h at ambient temperature under 
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Ar. Degassed PBS (10×) was added to make the entire reaction mixture 1× in PBS, and 
stirring was continued for 30 min. The concentration of Eu was verified by ICP-MS. 
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3.7 Estimating Rotational Correlation Time (τR) 
3.7.1 Theoretical Basis 
Inner-sphere relaxivity can be expressed by the following equation: 
Eq 3.2      -                    
    
 
    
(
 
       
)              
where q is the number of inner-sphere water molecules, T1m is the longitudinal relaxation 
time of a bound water molecule, τm is the residence lifetime of bound water molecules. 
Assuming that the inner-sphere relaxivity of a sample is contributing to half the observed 
relaxivity, r1,obs, Eq 3.2 can be rewritten as: 
Eq 3.3                   
 
    
(
 
       
)                            
where 1000 was used as a factor to convert mM unit in relaxivity to M. 
Solving for T1m: 
Eq 3.4       
 
(        )            
                       
There are two relaxation mechanisms of the bound water protons that depend on the 
interaction between the paramagnetic metal and the water proton—dipole–dipole (through 
space) and scalar (through bonds) and are expressed by the equation below: 
Eq 3.5  
 
   
  
 
  
     
 
  
          
 
  
                                                                  
The longitudinal relaxation rate of water proton due to dipole-dipole mechanism is 
described by the following equation: 
Eq 3.6  
 
  
     
 
  
(
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  )           
where    is the proton gyromagnetic ratio (2.67 × 10
8
 rad s
–1 
T
–1
),   is Bohr magneton 
(9.27 × 10
–24
 J T
–1
),      is the distance between Eu
2+
 and water proton (3.22 × 10
–10
 m), S 
is the spin number (3.5 for Eu
2+
),   is the magnetic permeability constant (4π × 10
–7 T•m 
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A
–1
),     and     are the longitudinal and transverse correlation times, respectively,    is 
the nuclear Larmor frequency (  multiplied with magnetic field strength , and    is the 
electronic Larmor frequency (  multiplied with magnetic field strength).  
The longitudinal and transverse correlation rates,       and        respectively  are 
mathematically described as: 
Eq 3.7  
 
   
  
 
  
  
 
   
  
 
  
                 
Eq 3.8    
 
   
  
 
  
  
 
   
  
 
  
                
where    is the rotational correlation time, and             are longitudinal and transverse 
electronic relaxation times, respectively. 
3.7.2 Calculating    using Microsoft Excel Spreadsheet 
1. Input the values of q (cell F1), r1(obs) (cell F2), taum (cell F3), g-factor (cell H1), 
r(EuH) (cell H2), and S (cell H3). Values for T1m (cell B1) and (1/T1m)/c (cell B4) will 
be automatically calculated. 
 
Note: Shown below are the MS excel functions for T1m (cell B1) and (1/T1m)/c (cell 
B4): 
Eq 3.9 T1m (cell B1): =(F1/(0.7*55.5*F2*1000))-F3 
where Eq 3.9 was based from Eq 3.4. (1/T1m)/c (cell B4) has the following formula: 
Eq 3.10 (1/T1m)/c (cell B4): =(1/B1)/((2/15)*(((267000000^2)*(H1^2)*((9.27E-
24)^2))/((H2)^6))*((0.0000001)^2)*(H3*(H3+1))) 
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Eq 3.10 is derived from Eq 3.6 and has the following equation: 
Eq 3.11  
 
   
 
 
 
  
   
 
  
(
  
     
 
    
 )      (
  
  
)
     
The derived equation shown in Eq 3.11 is equivalent to Eq 3.12 
Eq 3.12  ( 
   
    
    
   
   
    
    
  )                   
which is the basis for the function in cell B8: 
Eq 3.13  (1/T1m)/c (cell B4):  =(3*B12/(1+((F8)^2)*B12^2))+(7*B13)/(1+((F9)^2) 
*B13^2)             
2. Input the magnetic field strength, B, (cell H8) to compute for the nuclear and electronic 
Larmor frequency, proton LF (cell F8) and electron LF (cell F9), respectively. 
 
Note: Shown below are the MS excel functions for tc1 (cell B12) and tc2 (cell B12): 
Eq 3.14 tc1 (cell B12): =B17/(1+((1/F3)+(F12))*B17) 
Eq 3.15 tc2 (cell B13): =B17/(1+((1/F3)+(F13))*B17) 
Eq 3.14 and 3.15 are based from Eq 3.7 and 3.8. 
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3. Input the 1/T1e and 1/T2e values. 
 
4. Input tauR values until (1/T1m)/c value in cell B8 is equal to that in cell B4. 
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3.8 1H and 13C NMR Spectra of 3.4–3.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.14 
1
H NMR Spectrum of 3.4. 
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 Figure 3.15 
13
C NMR Spectrum of 3.4. 
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Figure 3.16 
1
H NMR Spectrum of 3.5. 
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Figure 3.17 
13
C NMR Spectrum of 3.5. 
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Figure 3.18 
1
H NMR Spectrum of 3.6. 
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Figure 3.19 
13
C NMR Spectrum of 3.6. 
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Figure 3.20 
1
H NMR Spectrum of 3.7. 
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Figure 3.21 
13
C NMR Spectrum of 3.7. 
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Figure 3.22 
1
H NMR Spectrum of 3.8. 
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Figure 3.23 
13
C NMR Spectrum of 3.8. 
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 Chapter Four 
Stability of Eu
2+
-Containing Cryptates 
Portions of this chapter were reprinted or adapted with permission from: 
Garcia, J.; Kuda-Wedagedara, A. N. W.; Allen, M. J. Physical Properties of Eu
2+
-
Containing Cryptates as Contrast Agents for Ultrahigh-Field Magnetic Resonance Imaging 
Eur. J. Inorg. Chem. 2012, 2012, 2135–2140. 
DOI: 10.1002/ejic.201101166 
Link: http://onlinelibrary.wiley.com/doi/10.1002/ejic.201101166/pdf 
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 
4.1 Introduction 
Kinetic stability, which relates to the inertness of a complex to transmetallation in vivo, 
is a critical parameter for contrast agents. Weaver and coworkers have reported the 
stability of cryptate Eu-4.1 in the presence of Na
+
, Ba
2+
, and tetraethylammonium cations, 
which are components of electrolytes in cyclic voltammetric experiments.
1
 However, the 
kinetic stability of Eu
2+
-containing cryptates in the presence of biologically relevant ions, 
which include Ca
2+
, Mg
2+
, and Zn
2+
, is of the utmost importance due to the toxicity of 
uncomplexed europium.
2
 Therefore, our kinetic studies explored the stability of the Eu
2+
-
containing complexes of cryptands 4.1–4.4, which contain a variety of functional groups 
(Figure 4.1), in the presence of Ca
2+
, Mg
2+
, and Zn
2+
. The use of these ligands allowed us 
to establish the relationship between the ligand structure and kinetic stability. Additionally, 
understanding the structural characteristics of Eu
2+
-containing cryptates that influence 
relaxivity as a function of pH value, temperature, and magnetic field strength is important 
because this knowledge should enable the design of improved ligands for use at ultrahigh 
field strengths. 
117 
 
 
Figure 4.1 Structures of cryptands 4.1–4.4. 
4.2 Synthesis 
The synthesis of cryptands 4.3 and 4.4 was performed by Akhila Kuda-Wedagedara, a 
graduate student of the Allen laboratory. To synthesize cryptands 4.3 and 4.4, a two-step 
synthetic procedure was used that involved thionyl chloride and 1,4,10,13-tetraoxa-7,16-
diazacyclooctadecane (diazacrown ether). Briefly, the diacids were converted into diacid 
chlorides followed by immediate reaction with diazacrown ether to produce the desired 
cryptands (Scheme 4.1). 
Scheme 4.1 Synthesis of 4.3 and 4.4. 
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4.3 Kinetic Stability Studies 
One critical feature of a useful contrast agent is its stability towards dechelation under 
physiological conditions. Although the thermodynamic stability constant of Eu–4.1 is high 
(log K = 13.0),
3
 kinetic stability is also crucial to evaluate the possibility of demetallation 
of contrast agents in the presence of endogenous ions. For a small-molecule contrast agent 
to be used in vivo, it should be kinetically inert for at least long enough to be excreted 
(t1/2 ≈ 5–6 min in mice, t1/2 ≈ 90 min in humans).
4
 Kinetic stability is important because 
uncomplexed Eu
2+
 oxidizes to Eu
3+
 more easily than Eu
2+
 that is encapsulated in 
cryptands,
5
 and Eu
3+
 is toxic.
2
 Prior to excretion, one possible pathway for the release of 
Eu
2+
 is through transmetallation with endogenous ions. Ions that are found in blood plasma 
include Ca
2+
, Mg
2+
, and Zn
2+
 and these are of particular concern because of their 
abundance in serum and their tendency to be complexed by ligands. Uncomplexed 
Ca
2+
 and Mg
2+
 ions, despite having a lower affinity than Zn
2+
 for many ligands,
6
 are 
present in higher concentrations than Zn
2+
 in blood serum (1.05, 1.34, and 0.125 mM for 
Ca
2+
, Mg
2+
, and Zn
2+
, respectively).
6–8
 However, the relatively low concentration of zinc in 
serum is sufficient to displace gadolinium in diethylenetriamine pentaacetate.
6,9
 Therefore, 
we have examined the stability of Eu
2+
-containing cryptates Eu–4.1–Eu–4.4 towards 
transmetallation by monitoring the change in the longitudinal relaxation rate of water 
protons at 60 MHz in the presence of Ca
2+
, Mg
2+
, and Zn
2+
 following the procedure of 
Muller and coworkers.
6,9
 An Eu
2+
-containing complex was prepared in degassed phosphate 
buffered saline (PBS) and other metals were added to the solution. The Eu
2+
 complexes are 
soluble in PBS, however, uncomplexed Eu
2+
 is insoluble, and upon transmetallation, it 
immediately precipitates.
10
 Once Eu
2+
precipitates, a measurable decrease in the relaxation 
rate of the water protons is detected. A plot of the ratio of the longitudinal relaxation rates 
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(R1p) of the Eu
2+
-containing solutions at a time (t) relative to initial values (t = 0) 
vs. t allows the extent of transmetallation to be monitored. Muller and coworkers 
developed this technique as a way to measure the degree of transmetallation in terms of the 
kinetic index, which is defined as the time required to reach 80% (at this point 80% of the 
Eu
2+
 is dechelated by transmetallion with the endogenous ions) of the initial longitudinal 
relaxation rate of water protons. We used concentrations of Ca
2+
, Mg
2+
, and Zn
2+
 that are 
2.38, 1.87, and 20 times greater than normal in vivo levels, respectively, and the results of 
our experiments are shown in Figures 4.2, 4.3, 4.4, and Table 4.1. 
 
Figure 4.2 Evolution of R1
p
(t)/R1
p
(t=0) versus time for the Eu
2+
-containing cryptates Eu–
4.1 (♦), Eu–4.2 (■), Eu–4.3 (▲), and Eu–4.4 (●) (2.5 mM) in the presence of Ca2+ (2.5 
mM). The horizontal line at 0.8 is the threshold for the kinetic index. Error bars represent 
standard error of the mean. 
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Figure 4.3 Evolution of R1
p
(t)/R1
p
(t=0) versus time for the Eu
2+
-containing cryptates Eu–
4.1 (♦), Eu–4.2 (■), Eu–4.3 (▲), and Eu–4.4 (●) (2.5 mM)  in the presence of Mg2+ (2.5 
mM). The horizontal line at 0.8 is the threshold for the kinetic index. Error bars represent 
standard error of the mean. 
 
Figure 4.4 Evolution of R1
p
(t)/R1
p
(t=0) versus time for the Eu
2+
-containing cryptates Eu–
4.1 (♦), Eu–4.2 (■), Eu–4.3 (▲), and Eu–4.4 (●) (2.5 mM) in the presence of Zn2+ (2.5 
mM). The horizontal line at 0.8 is the threshold for the kinetic index. Error bars represent 
standard error of the mean. 
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Table 4.1 Calculated %Eu
2+
 dechelated via transmetalation in the presence of Ca
2+
, Mg
2+
, 
and Zn
2+
 after 4740 min (Ca
2+
), 4770 min (Mg
2+
), and 4800 min (Zn
2+
) treatment of 2.5 
mM of the corresponding endogeneous ions. 
Complexes Ca
2+ 
(%) Mg
2+ 
(%) Zn
2+ 
(%) 
Eu–4.1 9 4 7 
Eu–4.2 17 8 14 
 
As seen from the ratio of the longitudinal relaxation rates vs. t (Figures 4.2, 4.3, 
and 4.4), the kinetic indices of Eu–4.1 and Eu–4.2 are greater than 4740 min in the 
presence of Ca
2+
, Mg
2+
, and Zn
2+
(Table 4.2), which is more than 53 times longer than the 
half-life of small molecules in vivo. This kinetic index indicates that Eu–4.1 and Eu–
4.2 did not fall below 80% of their efficacy during this time, which suggests that these 
complexes are inert to transmetallation in the presence of Ca
2+
, Mg
2+
, and Zn
2+
 at greater 
than normal in vivo levels. Interestingly, the values in the presence of Zn
2+
 appeared to 
decrease initially and then increase again; however, analysis of the variance revealed that 
all of the data points for Eu–4.1 and Eu–4.2 in the presence of Zn2+ are not different (α = 
0.01). The stability of these Eu
2+
-containing complexes is likely due to the effective 
binding of the cryptand to the metal ion. 
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Table 4.2 Kinetic index data.  
Complexes Ca
2+ 
(min) Mg
2+ 
(min) Zn
2+ 
(min) 
Eu–4.1 >4740 >4770 >4800 
Eu–4.2 >4740 >4770 >4800 
Eu–4.3 >0,<90 >0,<120 >0,<240 
Eu–4.4 >0,<90 >0,<120 >150,<240 
 
Although Eu–4.1 and Eu–4.2 showed stability towards transmetallation in the presence 
of endogenous metal ions, precipitates were observed as soon as PBS was added to Eu–
4.3 and Eu–4.4, consequently, these data are not included in Figures 4.1, 4.2, and 4.3. This 
observation suggests a weaker interaction between Eu
2+
 and amide-
containing 4.3 and 4.4 relative to 4.1 and 4.2. A further decrease in the longitudinal 
relaxation rate was observed in the presence of Ca
2+
, Mg
2+
, and Zn
2+
. Studies with Eu–
3 and Eu–4 were stopped once the longitudinal relaxation rate fell below 80 % of the initial 
value. 
The weak binding of Eu
2+
 to 4.3 and 4.4 can be attributed to the presence of amide 
groups in the cryptand structure. Amides have resonance structures (Figure 4.5) that 
change both the electronic and structural properties of the ligands relative to 4.1 and 4.2. 
Because of the presence of partial positive charges on nitrogen atoms, it is unlikely that 
these nitrogen atoms serve as donors. Thus, the denticity of 4.3 and 4.4 is decreased 
relative to that of 4.1 and 4.2. Furthermore, when the lone pairs on the nitrogen atoms are 
delocalized, the geometry of the nitrogen atoms changes from pyramidal to trigonal planar, 
and this change in geometry could also make it harder for Eu
2+
 to coordinate with 4.3 and 
4.4 relative to 4.1 and 4.2. Consequently, a decrease in the kinetic stability is observed. 
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Although amide-containing cryptands are not good ligands for Eu
2+
, Eu–4.1 and Eu–
4.2 were observed to have high kinetic stabilities in the presence of Ca
2+
, Mg
2+
, and Zn
2+
 in 
concentrations higher than those found in vivo, a promising result for their potential use as 
contrast agents. 
 
 
 
 
 
Figure 4.5 Contributing resonance structures of cryptands 4.3 and 4.4. 
4.4 Conclusion 
Eu
2+
-containing cryptates that have no amide moieties in their structures were 
kinetically stable in the presence of Ca
2+
, Mg
2+
, and Zn
2+
at concentrations 1.87–20 times 
higher than biological concentrations. In addition, transmetallation studies demonstrated 
that the kinetic stability of Eu
2+
-containing cryptates is affected by the presence of amides. 
4.5 Experimental Section 
4.5.1 Materials 
Commercially available chemicals were of reagent-grade purity or better and were used 
without further purification unless otherwise noted. Water was purified using a PURELAB 
Ultra Mk2 water purification system (ELGA). Dicholoromethane was dried using a solvent 
purification system (Vacuum Atmospheres Company) and degassed under vacuum. 
Triethylamine was distilled from CaH2 under an atmosphere of Ar.
11
 Flash 
chromatography was performed using silica gel 60, 230–400 mesh (EMD 
Chemicals).
12
 Analytical TLC was carried out with ASTM TLC plates precoated with 
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silica gel 60 F254 (250 μm layer thickness). TLC visualization was accomplished using a 
UV lamp followed by charring with potassium permanganate stain (2 g of KMnO4, 20 g of 
K2CO3, 5 mL of 5% w/v aqueous NaOH, 300 mL of H2O).  
4.5.2 Characterization 
1
H NMR spectra were obtained with a Varian Unity 400 (400 MHz) spectrometer, 
and 
13
C NMR spectra were obtained with a Varian Unity 400 (101 MHz) spectrometer. 
Chemical shifts are reported relative to residual solvent signals (CDCl3: 
1
H: δ = 7.27, 
13
C: δ = 77.23 ppm). 1H NMR spectroscopic data are assumed to be first order, and the 
apparent multiplicity is reported as d = doublet and m = multiplet. HRMS (ESI) were 
obtained with an electrospray time-of-flight high-resolution Waters Micromass LCT 
Premier XE mass spectrometer. Samples for inductively coupled plasma mass 
spectrometry (ICP-MS) were diluted using aqueous nitric acid (2 % v/v). Standard 
solutions were prepared by serial dilution of a Eu standard (High-Purity Standards). ICP-
MS measurements were conducted with a PE Sciex Elan 9000 ICP-MS instrument with a 
cross-flow nebulizer and Scott-type spray chamber. Longitudinal relaxation times, T1, were 
measured using standard recovery methods with a Bruker Minispec mq 60 [1.4 T] at 60 
MHz and 37 °C. 
4.5.3 Synthesis 
4,7,21,24-tetraoxa-13,16-dithia-1,10-diazabicyclo[8.8.8]hexacosane-11,18-dione (4.3). 
A solution of (ethylenedithio)diacetic acid (0.500 g, 2.38 mmol)  in thionyl chloride (5.0 
mL, 68 mmol)  under Ar was heated at reflux for 5 h. Excess thionyl chloride was removed 
under reduced pressure, and the residue was dissolved in anhydrous toluene  (40 mL). The 
resulting solution and a solution of 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane and 
triethylamine (1.5 mL, 0.010 mol, 4.2 equiv) in anhydrous toluene (40 mL) were added 
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simultaneously (50 mL/h) to a separate flask containing anhydrous toluene (100 mL) at 0–
5 
o
C under an Ar  atmosphere. The resulting solution was stirred for 12 h at ambient 
temperature. A yellow–orange suspension formed and was filtered, and the solvent from 
the filtrate was removed under reduced pressure. Purification using silica gel 
chromatography (10:1 CH2Cl2/methanol) yielded 0.215 g (43%) of 4.3 a fluffy yellow 
solid. 
1
H NMR (400 MHz, CDCl3, δ): 2.77–4.32 (m, CH2); 
13
C NMR (101 MHz, CDCl3, 
δ): 32.9 (CH2), 33.6 (CH2), 49.7 (CH2), 50.5 (CH2), 69.2 (CH2), 69.5 (CH2), 71.2 (CH2), 
71.4 (CH2), 170.7; TLC: Rf = 0.54 (10:1 CH2Cl2/methanol); HRESIMS (m/z): [M + Na]
+ 
calcd for NaC18H32N2S2O6, 459.1600;  found, 459.1602. 
5,6-benzo-4,7,13,16,20,23-hexaoxa-1,10-diazabicyclo[8.8.8]hex-acosane-2,9-dione 
(4.4). A solution of catechole-1,4-o,o-diacetic acid (0.40 g, 1.8 mmol) in thionyl chloride 
(5.0 mL, 68 mmol) under Ar was heated at reflux for 5 h. Excess thionyl chloride was 
removed under reduced pressure, and the residue was dissolved in anhydrous toluene (25 
mL). The resulting solution and a solution of 1,4,10,13-tetraoxa-7,16-
diazacyclooctadecane (0.32 g, 1.2 mmol, 1.0 equiv) and triethylamine (0.50  mL, 3.3 
mmol, 2.4 equiv)  in anhydrous toluene (25 mL) were added simultaneously (50 mL/h) to a 
separate flask containing anhydrous toluene (60 mL) at 0–5 oC under an Ar  atmosphere. 
The solution was stirred for 12 h at ambient temperature. An orange suspension formed 
and was filtered, and the solvent was removed under reduced pressure. Purification using 
silica gel chromatography (9:1 CH2Cl2/methanol) yielded 0.144 g (36%) of 4.4 a fluffy 
white solid. 
1
H NMR (400 MHz, CDCl3, δ): 2.77–3.22 (m, CH2, 2H), 3.37–3.83 (m, CH2, 
20H), 4.08–4.35 (m, CH2, 2H), 4.64–4.91 (m, CH2, 2H), 5.15–5.23 (d, J = 14.4 Hz, CH2, 
2H), 6.86–7.10 (m, CH, 4H); 13C NMR (101 MHz, CDCl3, δ): 48.5 (CH2), 48.9 (CH2), 
68.1 (CH2), 69.4 (CH2), 69.7 (CH2), 71.1 (CH2), 71.3 (CH2), 116.1 (CH), 122.2 (CH), 
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148.3, 169.0; TLC: Rf  = 0.8 (9:1 CH2Cl2/methanol); HRESIMS (m/z): [M + Na]
+ 
calcd for 
NaC22H32N2O8,  475.2062;  found,  475.2060. 
General Procedure for the Synthesis of Eu–4.1–Eu–4.4: A degassed aqueous solution of 
EuCl2 (1 equiv.) was mixed with a degassed aqueous solution of a cryptand (2 equiv.). The 
resulting mixture was stirred for 12 h at ambient temperature under Ar. Degassed PBS 
(10×) was added, and stirring was continued for 30 min. The concentration of Eu in the 
resulting solution was verified by ICP-MS, and the solution was used directly for relaxivity 
measurements. For transmetallation experiments, the same procedure was followed with 
only 1 equiv. of ligand. 
4.5.4 Transmetallation Kinetics 
The following procedure was adapted from Muller and coworkers.
9
 A stock solution of 
the Eu
2+
-containing cryptate (5 mM) was prepared in degassed PBS under an Ar 
atmosphere. To an aliquot of this solution was added a solution of Ca
2+
 (12.1 mM) in 
degassed PBS such that the resulting solution was 2.5 mM in both Eu
2+
 and Ca
2+
. This 
solution was stirred at 37 °C under Ar. Aliquots were taken at 90, 180, 420, 1500, 3300, 
and 4740 min after the addition of Ca
2+. All aliquots were filtered using 0.2 μm filters prior 
to T1 measurements. The t1 value of these aliquots (60 MHz, 37 °C) was immediately 
measured at each time point. The experiment was triplicated with independently prepared 
solutions. The entire procedure was repeated using Mg
2+
 (16.4 mM) and Zn
2+
 (9.97 mM) in 
place of Ca
2+
 (12.1 mM). Statistical analysis of variance was performed using the program 
found at faculty.vassar.edu/lowry/anova1u.html. 
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4.7
 1
H and 
13
C NMR Spectra of 4.3 and 4.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.6 
1
H NMR Spectrum of 4.3. 
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Figure 4.7 
13
C NMR Spectrum of 4.3. 
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 Figure 4.8 
1
H NMR Spectrum of 4.4. 
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Figure 4.9 
13
C NMR Spectrum of 4.4. 
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Chapter Five 
Interaction of Biphenyl Functionalized Eu
2+
-Containing Cryptate with Albumin 
Binding: Implications to Contrast Agents in MRI 
Reprinted from Inorg. Chim. Acta, 393, Garcia, J.; Allen, M. J., Interaction of biphenyl-
functionalized Eu
2+
-containing cryptate with albumin: Implications to contrast agents in 
magnetic resonance imaging, 324–327, 2012. Copyright (2012), with permission from 
Elsevier. 
5.1 Introduction 
Magnetic resonance imaging (MRI) is a noninvasive imaging modality that can be used 
to study anatomical structures,
1
 and the use of ultra-high field strength (≥7 T) magnets 
enables faster acquisition of MR images with increased spatial resolution.
2–4
 However, 
common contrast agents such as low-molecular-weight Gd
3+
-containing complexes 
become less efficient at ultra-high field strengths relative to lower field strengths.
5
 Unlike 
these Gd
3+
-based contrast agents, Eu
2+
-containing cryptates have higher relaxivity values 
at ultra-high field strengths (7 and 9.4 T) than at lower field strengths (1.4 and 3 T).
6–7 
I hypothesized that the relaxivity of Eu
2+
-containing cryptates could be increased by 
using strategies that improve the relaxivity of Gd
3+
-based agents. One of these strategies is 
the slowing of molecular-tumbling rate that can be influenced by covalent or noncovalent 
interactions with macromolecules including proteins.
1,8–27
 Human serum albumin (HSA), 
the most abundant protein in plasma with concentration of ∼670 μM or 4.5% (w/v),16 
noncovalently binds to some contrast agents that contain lipophilic moieties.
16–25
 McMurry 
and coworkers reported an increase in relaxivity of over 200% as a result of the 
noncovalent interaction of albumin with a Gd
3+
-containing complex functionalized with 
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biphenyl.
25
 Because of the work with Gd
3+
 and the ability to influence the properties of 
Eu
2+
 with functionalized cryptands,
28
 we hypothesized that a cryptand with a biphenyl 
group would produce a Eu
2+
complex that interacts with albumin to result in an increase in 
relaxivity. 
To test my hypothesis, I synthesized biphenyl-modified Eu
2+
-containing 
cryptate 5.1 (Figure 5.1), and measured the relaxivity of cryptate 5.1 in the presence and 
absence of HSA at different field strengths (1.4, 3, 7, 9.4, and 11.7 T). I compared the 
resulting relaxivity values to estimates calculated using the Solomon–Bloembergen–
Morgan equations.
29
 I also illustrated the effect of albumin on the contrast-enhancing 
ability of 5.1 using phantom images acquired at 7 T. Finally, I performed variable-
temperature 
17
O NMR experiments that probed the molecular basis of the relaxivity values 
of complex 5.1 in the presence and absence of HSA. 
 
Figure 5.1 Structure of biphenyl-functionalized Eu
2+
-containing complex 5.1. 
5.2 Results and Discussion 
Biphenyl-functionalized cryptate 5.1 was designed based on the structure of Gd
3+
-
based contrast agents that interact with HSA. These Gd
3+
-containing albumin-binding 
contrast agents contain lipophilic aryl groups such as the biphenyl moiety that enable them 
to interact with HSA.
16–25
 Therefore, I expected that the lipophilic biphenyl moiety in 
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cryptate 5.1 would enable investigation of the effect of albumin binding on the relaxivity 
of Eu
2+
 at different field strengths. 
5.2.1 Influence of Magnetic Field on the Relaxivity of 5.1 and 5.1–HSA  
The relaxivity, r1, of 5.1 in PBS in the presence and absence of HSA was measured at 
multiple field strengths, and because not all of the magnets were capable of variable-
temperature measurements, I separated data into Figure 5.2a and 5.2b so that 
measurements obtained at each temperature could be compared. In the absence of HSA, 
the r1 of 5.1 at 20 °C is higher at 7 and 9.4 T than at 3 T suggesting that this complex is 
more efficient at ultra-high field strengths than at lower field strengths (Figure 5.2a). 
However, I found that the r1 values at 3 and 11.7 T were not different (Student t test). 
Moreover, the relaxivity of 5.1 as a function of field strength is similar to other Eu
2+
-
containing cryptates in the same conditions.
7
 In the presence of HSA (4.5% w/v), the 
relaxivity of 5.1 decreased by 24.8 ± 0.6% to 40.2 ± 0.2% at field strengths of 3, 7, 9.4, and 
11.7 T (Figure 5.2a). However, at 37 °C and 1.4 T, the r1 of 5.1 in the presence of albumin 
was 171 ± 11% higher than in the absence of HSA (Figure 5.2b). An increase of 218% in 
relaxivity (measured at 37 °C and 0.47 T MHz) was reported by McMurry and coworkers 
for a Gd
3+
-containing complex functionalized with biphenyl in the presence of albumin.
25
 
McMurry’s report and the relaxation data of 5.1 at 1.4 T indicate that the observed 
relaxation enhancement of 5.1 in the presence of HSA is likely due to the interaction of the 
biphenyl moiety of Eu
2+
cryptate with albumin.
30
 However, the relaxivity of 5.1 was 
15.2 ± 0.5% and 49.8 ± 0.2% lower in the presence of HSA at 37 °C and 9.4 T and 11.7 T, 
respectively. The observed decreasing trend in relaxivity of 5.1 in the presence of HSA at 
37 °C as a function of field strength is consistent with the trend obtained by calculating the 
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relaxivity of a slowly rotating Eu
2+
-containing cryptate at multiple field strengths using the 
Solomon–Bloembergen–Morgan equations (Figure 5.2b and Table 5.1). 
 
Figure 5.2 (a)  Proton longitudinal relaxivity (20 °C, pH = 7.4) of biphenyl-functionalized 
cryptate 5.1 in the absence (○) and presence (□) of HSA as a function of magnetic field 
strength. (b) Proton longitudinal relaxivity (37 °C, pH = 7.4) of biphenyl-functionalized 
cryptate 5.1 in the absence (○) and presence (□) of HSA as a function of magnetic field 
strength. Simulated relaxivity values (■) of a slowly rotating Eu2+-containing complex at 
37 °C. Values at 1.4, 3, 7, and 11.7 T without HSA are from Ref. 6. HSA concentration 
was 4.5% (w/v). Error bars represent standard error of the mean of 3–9 independently 
prepared samples. 
5.2.2 Albumin Titration 
To better understand the effect of albumin on the relaxivity of 5.1, titration experiments 
were performed using different percentages (2, 4.5, 6, 10, 15, and 25% w/v) of HSA while 
keeping the concentration (1 mM) of cryptate 5.1 constant. In preparation of 5.1, two 
equivalents of the biphenyl cryptand were used for each equivalent of Eu
2+
 to facilitate 
metalation of the biphenyl cryptand; therefore, the samples 2, 4.5, 6, and 10% HSA have 
an excess of biphenyl relative to HSA (HSA/5.1 < 1 except 10% HSA sample) and 
samples with 15 and 25% HSA have a subcess of biphenyl relative to HSA (HSA/5.1 > 1). 
The MR images (Figure 5.3a) of 5.1 with HSA/5.1 ratios less than one have higher signal 
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intensities as compared to the images of samples with HSA/5.1 ratios greater than 1. To 
quantify this observation, the proton longitudinal relaxation rate, 1/T1, of the sample with 
the lowest HSA/5.1 ratio is 102.7 ± 0.3% higher than the sample with the highest 
HSA/5.1 ratio and 47.0 ± 0.2% higher than the other sample (15% HSA) that has an excess 
of HSA relative to biphenyl (Figure 5.3b). The difference in signal intensity and 
1/T1 values among the samples indicate that the presence of albumin affects the relaxivity 
of complex 5.1 and does not translate to a higher signal intensity and higher efficacy 
of 5.1 at ultra-high fields. These observations support the relaxivity measurements 
described in Figure 5.1. 
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Figure 5.3 (a) T1-weighted MR images of albumin-containing solutions of biphenyl-
functionalized cryptate 5.1 at 7 T and 20 °C. The diameter of the tubes that were used for 
imaging was 6 mm. Imaging parameters were TR = 21 ms; TE = 3.26 ms; and 
resolution = 0.27 × 0.27 × 2 mm
3
. (b) Proton longitudinal relaxation rate (20 °C, pH = 7.4) 
as a function of % HSA at 7 T. The concentration of cryptate 5.1 was 1 mM. Error bars 
represent standard error of the mean of three samples. 
a
No cryptate. 
5.2.3 
17
O NMR Spectroscopy 
To explain the observations of relaxivity, I performed variable-temperature 
17
O NMR 
measurements using a sample of 5.1 in PBS and 5.1 in PBS with 25% HSA. I chose 25% 
HSA because the majority of 5.1 was expected to be bound to albumin at this percentage,
25
 
and the 
17
O NMR data obtained from this sample would be representative of the molecular 
properties of cryptate 5.1 that is bound to HSA. The molecular properties that influence 
relaxivity that were studied using variable-temperature 
17
O NMR spectroscopy were the 
residence lifetime of bound water molecules, τm
298
; the water-exchange rate, kex
298
 = 
139 
 
1/τm
298
; and the number of inner-sphere water molecules, q (Table 5.1). While the 
residence lifetime of bound water of cryptate 5.1 was not different (Student t test) in the 
presence and absence of albumin, the number of inner-sphere water molecules was reduced 
from two to one upon addition of albumin indicating that the observed decrease in 
relaxivity for cryptate 5.1 in the presence of albumin at 3, 7, 9.4, and 11.7 T is likely 
caused by the displacement of inner-sphere water molecules from the Eu
2+
 complex. 
Moreover, the residence lifetime of bound water was not different in the presence or 
absence of albumin suggesting that protein side chains do not hinder the remaining bound 
water molecule from exchanging with the bulk solvent. With the water-exchange rate and 
the number of inner-sphere water molecules of 5.1 in the presence of HSA remaining 
constant at different field strengths, the relaxivity enhancement observed at 1.4 T likely 
can be attributed to the enhanced contribution of rotational correlation rate at this field 
strength. 
Table 5.1 Results of 
17
O NMR experiments of cryptate 5.1 with and without albumin. 
 5.1
a 
5.1–HSAb  
τm
298
 (ns) 48 ± 4 40 ± 7 
kex
298
 (10
8
 s
–1
) 0.21 0.25 
q 2 1 
∆H (kJ/mol) 70 ± 2 62 ± 8 
 
a 
Reference 6, 
b
HSA concentration was 25% (w/v) 
5.3 Conclusions 
The relaxation profile of Eu
2+
-containing cryptate 5.1 in the absence of albumin shows 
that cryptate 5.1 is more efficient at higher field strengths (7 and 9.4 T) than at lower field 
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strengths (1.4 and 3 T). MR images and 1/T1 values of samples with different 
HSA/5.1 ratios suggest that possible interaction of 5.1 with HSA occurs, but this 
interaction does not lead to an increase in relaxivity of Eu
2+
 at higher field strengths 
(⩾3 T). However, in the presence of albumin, an increase in relaxivity of 5.1 is only 
observed at 1.4 T likely due to decreased rotational correlation rate values, and a decrease 
in relaxivity was observed at 3, 7, 9.4, and 11.7 T because of a decreased water-
coordination number. These data are in agreement with calculations made using the 
Solomon–Bloembergen–Morgan equations. Studies using different lengths of linkers 
between the biphenyl and cryptate could provide a good insight on the influence of 
albumin interaction on the relaxivity of cryptate 5.1. Also, binding a Eu
2+
-containing 
cryptate to different sizes of macromolecules could provide a better understanding on the 
effect of macromolecular binding on the relaxivity of Eu
2+
-containing cryptates at higher 
fields. These studies are currently underway in our laboratory. 
5.4 Experimental Section 
5.4.1 Materials 
Commercially available chemicals were of reagent-grade purity or better and were used 
without further purification unless otherwise noted. Biphenyl-functionalized cryptand and 
cryptate 5.1 were prepared following a published procedure presented in chapter 3 of this 
thesis. 
5.4.2 Concentrations 
Samples for inductively coupled plasma mass spectrometry (ICP-MS) were diluted 
using aqueous nitric acid (2% v/v). Standard solutions were prepared by serial dilution of a 
Eu standard (high-purity standards). ICP-MS measurements were conducted on a PE Sciex 
Elan 9000 ICP-MS instrument with a cross-flow nebulizer and Scott-type spray chamber. 
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5.4.3 Preparation of HSA samples 
Stock solutions of HSA (30% w/v) and (35% w/v) were prepared by dissolving 300 
and 350 mg of HSA, respectively in 1 mL of 1× degassed phosphate buffered saline (PBS). 
An aliquot of the stock HSA solution was added to a solution of 5.1 in degassed PBS to 
produce the desired concentrations of 5.1 and HSA. 
5.4.4 Preparation of Sr
2+
 analogue of 5.1 
A degassed aqueous solution of SrCl2 (1 equiv, 41.2 mM) was mixed with a degassed 
aqueous solution of the biphenyl cryptand (2 equiv, 34.2 mM). The resulting mixture 
(1 mM SrCl2 and 2 mM cryptand) was stirred for 12 h at ambient temperature under Ar. 
Degassed PBS (10×) was added to make the entire reaction mixture 1× in PBS, and stirring 
was continued for 30 min. The concentration of Sr in the resulting solution was verified by 
ICP-MS. 
5.4.5. T1 and relaxivity measurements 
Longitudinal relaxation times, T1, were measured using standard recovery methods 
with a Bruker Minispec mq 60 (1.4 T) at 60 MHz and 37 °C; a Varian Unity 400 (9.4 T) at 
400 MHz and 20 and 37 °C; and a Varian 500S (11.7 T) at 500 MHz and 20 and 37 °C. 
The slope of a plot of 1/T1 versus concentration of Eu was used to calculate relaxivity. 
Four to six different concentrations of Eu (0–10 mM) were used, and measurements were 
repeated 3–9 times with independently prepared samples. 
Susceptibility weighted imaging (SWI) was performed at 3 (Siemens TRIO) and 7 T 
(ClinScan) using volume coils. The acquisition parameters were as 
follows: TR = 37 ms, TE = 5.68–31.18 ms, and resolution = 0.5 × 0.5 × 2 mm
3
 for 3 T; 
and TR = 21 ms, TE = 3.26–15.44 ms, and resolution = 0.27 × 0.27 × 2 mm
3
 for 7 T. 
Multiple flip angles (5, 10, 15, 20, 25, and 30°) were used in the SWI experiments to allow 
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for the determination of longitudinal relaxation time, T1.
31
 MR images were processed 
using SPIN software (SVN Revision 1751). Matlab (7.12.0.635 R2011a) was used to 
generate effective transverse relaxation time, T2∗, and corrected T1 maps. The 1/T1 values 
from the corrected T1 maps were plotted versus the concentration of Eu in the samples to 
calculate longitudinal relaxivities, r1, as previously reported in chapter 3 of this document.
6 
5.4.6. Variable-temperature 
17
O NMR experiments 
Variable-temperature 
17
O NMR measurements of solutions of 5.1-HSA (1 mM 5.1, 
25% HSA) and its Sr
2+
analogue (1 mM Sr
2+
-cryptate, 25% HSA) in degassed PBS (pH 
7.4) were obtained on a Varian-500S (11.7 T) spectrometer. 
17
O-enriched water (10% 
H2
17
O, Cambridge Isotope Laboratories, Inc.) was added to samples to yield 1% 
17
O 
enrichment. Transverse 
17
O relaxation rates were measured at 15, 25, 30, 35, 40, 45, and 
50 °C. The Sr
2+
 analogue of 5.1-HSA was used as diamagnetic reference. A/ħ was fixed to 
−4.1 × 10−6 rad/s.32 The least-squares fits of the 17O NMR relaxation data were calculated 
using Origin software (8.0951 B951) following published procedures.
33 
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Table 5.2. Variable-temperature 
17
O NMR Data for Cryptate 5.1 and Sr
2+
 analogue of 5.1 
in the presence of albumin. 
Temperature (°C) Linewidth of 
17
OH2 (Hz) 
Sr
2+ 
analogue of 5.1–HSA 5.1–HSA 
50 57.85 60.44 
45 65.03 68.09 
40 73.78 77.40 
35 84.57 89.24 
30 96.26 102.35 
25 111.44 119.16 
15 151.97 160.28 
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Figure 5.4. Variable-temperature 
17
O NMR Fittings for cryptate 5.1 in the presence of 
albumin. 
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Chapter Six 
Summary of Findings and Future Outlook 
6.1 Summary of Findings 
 Magnetic resonance imaging (MRI) cannot always differentiate pathological from 
healthy tissues, and therefore contrast agents are used to enhance image contrast. However, 
the contrast-enhancing ability of clinically approved contrast agents decreases dramatically 
at higher field strengths where better resolution and shorter scan times are accessible. 
Therefore, there is a need to develop T1-reducing (positive) contrast agents that perform 
well in the ultra-high field strength regime. This thesis describes my efforts with respect to 
the coordination chemistry necessary to pursue an answer to this need. 
I measured the relaxivity of small Eu
2+
-containing cryptates at field strengths that 
are commonly used for clinical imaging and at field strengths that are used in preclinical 
research. These studies demonstrated that these cryptates have higher relaxivity at ultra-
high field strengths relative to lower fields. In addition, these cryptates showed higher 
efficiency at high and ultra-high field strengths relative to a clinically approved contrast 
agent, gadolinium(III) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate. Because of 
these promising results, I also measured the relaxivity of small Eu
2+
-containing cryptates at 
different temperatures and pH values. Relaxivity data showed that the contrast-enhancing 
ability of these cryptates decreases as temperature increases, as predicted by theory, but is 
not affected by changes in pH under physiologically relevant range.  
 The relaxometric studies described in this thesis demonstrated the basis of using 
Eu
2+
-containing cryptates as contrast agents at ultra-high field strength MRI. Through my 
studies, the scientific community is able to gain additional understanding of the 
performance of Eu
2+
-containing cryptates at field strengths accessible to clinical and 
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preclinical imaging. This knowledge should aid in the design of more efficient Eu
2+
-
containing cryptates. 
 To explain the results of my relaxometric experiments, I performed variable-
temperature 
17
O NMR and electron paramagnetic resonance (EPR) spectroscopy. These 
spectroscopic techniques are crucial in understanding the influence of molecular 
parameters including the number of inner-sphere water molecules, water-exchange rate, 
electron-spin relaxation times, and rotational-correlation rate to the relaxivity of Eu
2+
-
containing cryptates. These experiments demonstrated the presence of two inner-sphere 
water molecules in each cryptate and near-optimal water-exchange rates for field strengths 
above 3 T. Both of these properties are desirable features of an effective contrast agent. In 
addition to the determination of the number of inner-sphere water molecules and water-
exchange rate, EPR measurements were performed to determine electronic parameters 
including the g factor and transverse electronic relaxation time. With the relaxivity and 
NMR and EPR data, rotational-correlation rates were estimated and were found to limit the 
relaxivity of these small Eu
2+
-containing cryptates. 
 With the understanding that these cryptates can potentially serve as contrast agents 
based on relaxivity data, I also determined the stability of these Eu
2+
-containing complexes 
towards transmetallation in the presence of the biologically relevant metal ions Ca
2+
, Mg
2+
, 
and Zn
2+
. This transmetallation experiment was important because of the toxicity of 
unchelated Eu
2+
, the abundance of Ca
2+
and Mg
2+
 in plasma, and the tendency of Zn
2+
 to 
chelate organic ligands. In this experiment, I found that amine-containing cryptates are 
inert to transmetallation and have longer transmetallation half-lives compared to non-
macrocyclic, clinically approved Gd
3+
-containing complexes including gadolinium(III) 
diethylenetriaminepentaacetate. 
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 Finally, because I observed that the efficiency of small molecular weight cryptates 
increases with molecular weight, I studied the contrast-enhancing ability of a biphenyl-
functionalized cryptate that can bind to macromolecules. I studied the relaxivity of this 
system in the presence of human serum albumin at multiple field strengths, performed 
albumin titration experiments, and used variable-temperature 
17
O NMR and EPR 
spectroscopies to understand the effect of albumin binding on the molecular parameters 
that influence relaxivity. These studies revealed a decrease in relaxivity in the presence of 
albumin that was likely due to the displacement of an inner-sphere water molecule. 
However, an increase in relaxivity in the presence of albumin was observed at 1.4 T. This 
change was attributed to the enhanced contribution of rotational correlation rate to 
relaxivity. This work opens an avenue of research for understanding the effect of 
macromolecular binding to the efficiency of these cryptates as contrast agents and to gain 
an improved understanding of the relaxivity–molecular weight relationship for these 
cryptates. 
 6.2 Future Outlook 
 The increase in relaxivity for Eu
2+
-containing cryptates at ultra-high field strengths 
is one of a few examples of paramagnetic materials exhibiting an increase in relaxivity as 
field strength increases in the ultra-high field strength regime. While the result is 
interesting, it is not yet fully understood why this increase in relaxivity is observed for 
these cryptates. Determining the relaxation profiles of other Eu
2+
-containing cryptates with 
molecular weights of more than 500 Da could yield insight with respect to the relaxivity of 
these cryptates. These studies could be achieved by binding cryptates to supramolecular 
systems or by covalently attaching cryptates to polymers. Relaxation profiles of the 
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resulting macromolecular systems could be determined by nuclear magnetic relaxation 
dispersion (NMRD) relaxometry and high-field NMR spectroscopy. 
In addition to the relaxometric studies in the preceding chapters, I synthesized 
dimeric and trimeric ligands to gain an understanding of the relaxivity–molecular weight 
relationship for Eu
2+
-containing cryptates. However, obtaining pure ligands using size 
exclusion chromatography remained elusive, and unequivocal characterization of 
metalated ligands is a challenging task. I suggest using reverse phase chromatography as 
an alternative way of purifying these oligomers. Also, dialysis using membranes of 500–
1000 molecular weight cutoff could also be used for purification. The metalated ligands 
could be characterized by elemental analysis. Differentiating bimetalated ligands to 
monometalated and unmetalated ligands could be made by comparing the sulfur to 
europium ratio in the elemental analysis. This characterization requires the metalation to be 
performed, using an excess of europium(II) to facilitate metalation, in water rather than in 
phosphate buffered saline. After metalation, dialysis should be performed using 500 Da 
molecular cutoff to remove unchelated europium.  
To further boost the utility of Eu
2+
-containing cryptates, I studied the relaxivity of a 
biphenyl-functionalized cryptate in the presence of human serum albumin. The albumin 
studies demonstrated that the decrease in relaxivity for the biphenyl-functionalized cryptate 
in the presence of albumin could be ascribed to displacement of an inner-sphere water 
molecule as indicated by the variable-temperature 
17
O NMR spectroscopy results. This loss 
of an inner-sphere water molecule could be due to the short linker that connects the 
biphenyl moiety and Eu
2+
 in the cryptand. The use of longer linkers could prevent inner-
sphere water molecules from being displaced from the complex.  
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In addition to the transmetallation studies that I performed in the presence of 
physiological cations, it  is also important to study the effect of physiologically relevant 
anions such as citrate, malonate, carbonate, or lactate on the kinetic stability of Eu
2+
-
containing cryptates. These ions are of particular concern if the cryptates have net positive 
charges because the affinity of the anions would be higher. While the presence of 
phosphate does not displace inner-sphere water molecules from the cryptates that I studied, 
other anions could compete with the cryptand for Eu
2+
, resulting in insoluble adducts. The 
transmetallation experiments described in this thesis could be adapted to study anions, and 
the results of these transmetallation studies would provide an understanding of the effect of 
different anions on the stability of Eu
2+
-containing cryptates.  
Finally, it is important to investigate the toxicity profile of the synthesized Eu
2+
-
containing cryptates by determining the maximum tolerated dose. These studies would 
help determine the effect of cryptate structure on toxicity. In addition, the use of 
antioxidants in the toxicity studies could provide information regarding the extent that 
antioxidants prolong the oxidation half-life of cryptates and lessen toxicity. Preliminary in 
vitro studies of cryptates in the presence of reduced glutathione demonstrated that reduced 
glutathione prolongs the oxidation half-life Eu
2+
-containing cryptates. The information that 
will be obtained from toxicity studies of Eu
2+
-containing cryptates would be useful for in 
vivo applications. 
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APPENDIX A 
MATLAB CODES FOR GENERATING T2
*
 AND T1 MAPS 
T2*: 
% function [T2map error_estimatemap]=flash_fit(fa,s,tr) 
% s is the 3D matrix of # of slices equal to the nsumber of flip angles. 
clear all; 
  
clc 
format long; 
  
h=msgbox(' --------Please enter the information Asked for ---------'); 
  
waitfor(h); 
  
rows=input('Enter Matrix size # ROWS: '); 
  
cols=input('Enter Matrix size # COLS: '); 
  
echonumber=input('Enter number of echoes: '); 
  
slices=input('Enter the number of slices in each echo images: '); 
  
s.fpathname=[]; 
  
%%%%%%%%%% FILE INFORMATION INPUT 
for i=1:echonumber 
    disp(' ');disp(' ');disp(' ') 
    display('Select the first file in the series you want to calculate T2*'); 
    [fname, path]=uigetfile('C:\Archives\Ang Doktorado\Projects\Imaging 
Experiments\2011 05 20 Phantom Imaging 3T\DICOM\5-
11Echo_SWI_FA5_.5x.5x2\TEsorted\*.*'); 
    s(i).fpathname=strcat(path,fname) 
    disp(' ');disp(' ');disp(' '); 
    TE(i)=input('\n Please enter the Corresponding echo time (TE) : '); 
end 
  
mm=zeros(rows,cols); 
mm1=zeros(rows,cols); 
  
%%%%%%%%%%%%%%%%%% ACTUAL CALCULATION WITH ALPHA MAP COMPENSATION INCLUDED 
for i=1:slices 
  
    mat=zeros(rows,cols); % IMAGE MATRIX SIZE 
    xmat=zeros(size(TE,2),rows,cols); % IMAGE MATRIX SIZE 
    ymat=zeros(size(TE,2),rows,cols); % IMAGE MATRIX SIZE 
  
    for j=1:echonumber 
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        if s(j).fpathname(size(s(j).fpathname,2)-7)=='-' 
            firstnum=str2num(s(j).fpathname(size(s(j).fpathname,2)-
6))*100+str2num(s(j).fpathname(size(s(j).fpathname,2)-
5))*10+str2num(s(j).fpathname(size(s(j).fpathname,2)-4)); 
            
mat(:,:)=dicomread(strcat(s(j).fpathname(1,1:(size(s(j).fpathname,2)-
7)),num2str(firstnum+i-1),'.dcm')); 
        elseif s(j).fpathname(size(s(j).fpathname,2)-6)=='-' 
            firstnum=str2num(s(j).fpathname(size(s(j).fpathname,2)-
5))*10+str2num(s(j).fpathname(size(s(j).fpathname,2)-4)); 
            
mat(:,:)=dicomread(strcat(s(j).fpathname(1,1:(size(s(j).fpathname,2)-
6)),num2str(firstnum+i-1),'.dcm')); 
        else s(j).fpathname(size(s(j).fpathname,2)-5)=='-' 
            firstnum=str2num(s(j).fpathname(size(s(j).fpathname,2)-4)); 
            
mat(:,:)=dicomread(strcat(s(j).fpathname(1,1:(size(s(j).fpathname,2)-
5)),num2str(firstnum+i-1),'.dcm')); 
        end 
     
        ymat(j,:,:)=log(mat); 
        xmat(j,:,:)=-TE(j); 
  
        %         end 
    end 
  
    clear  mat tmps tmpt; 
  
    num=echonumber*sum((xmat.*ymat),1)-(sum(xmat,1).*sum(ymat,1)); 
    din=echonumber*(sum(xmat.^2,1))-(sum(xmat,1)).^2; 
  
    b1=num./din; 
  
    b2=(1/echonumber)*(sum(ymat,1)-b1.*sum(xmat,1)); 
  
    T2map=(1./b1); 
    %     T1map=-tr./(log(b1)); %%%%% TR OF THE EXPERIMENT 
  
    mm(:,:)=T2map(1,:,:); 
    clear T2map; 
    T2map=mm; 
  
%     mm(:,:)=echoimagemat(1,:,:); 
%     mm1(:,:)=echoimagemat(2,:,:); 
%  
%     T2_error= (T2map/dTE).*sqrt( (sigma1./mm).^2 + (sigma2./mm1).^2 ); 
  
  
    curntfname=strcat(s(1).fpathname(1,(1:size(s(1).fpathname,2)-
7)),'T2_map_mult10-',num2str(i),'.ima'); 
    writeima(curntfname, T2map*100); 
%     dicomwrite(T2map*100,curntfname); 
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%     curntfname=strcat(s(1).fpathname(1,(1:size(s(1).fpathname,2)-
7)),'T2_errmap_mult10-',num2str(i),'.dcm'); 
%     %     writeima(curntfname, T2_error*10); 
%     dicomwrite(T2map,curntfname); 
end 
 
  
 
 
 
T1 map (with T2* correction): 
% function [T1map error_estimatemap]=flash_fit(fa,s,tr) 
% s is the 3D matrix of # of slices equal to the number of flip angles. 
clear all; 
  
clc 
format long; 
  
h=msgbox(' --------Please enter the information Asked for ---------'); 
  
waitfor(h); 
  
rows=input('Enter Matrix size # ROWS: '); 
  
cols=input('Enter Matrix size # COLS: '); 
  
TE=input('Enter Echo-time: '); 
  
fanumber=input('Enter number of flip angles: '); 
slices=input('Enter the number of slices in the Flip angle images: '); 
  
s.fpathname=[]; 
  
display('Please input the T2starcorrection file (.ima)'); 
[fnameT2star, pathT2star]=uigetfile('C:\Archives\Ang 
Doktorado\Projects\Imaging Experiments\2011 05 20 Phantom Imaging 
3T\DICOM\*.*'); 
fpathnameT2star=strcat(pathT2star,fnameT2star) 
t2starcorrection=showima(fpathnameT2star); 
  
  
%%%%%%%%%% FILE INFORMATION INPUT 
for i=1:fanumber 
    disp(' ');disp(' ');disp(' ') 
    display('Select the first file in the series you want to calculate T1'); 
    [fname, path]=uigetfile('C:\Archives\Ang Doktorado\Projects\Imaging 
Experiments\2011 05 20 Phantom Imaging 3T\DICOM\*.*'); 
    s(i).fpathname=strcat(path,fname) 
    disp(' ');disp(' ');disp(' '); 
    fa(i)=input('\n Please enter the Corresponding Flip angle:    '); 
end 
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% disp(' ');disp(' '); 
% disp('Select the corresponding first reference flip angle image for 
normalization:'); 
% fa=(fa)*(pi/180); 
  
% [fname, path]= uigetfile('E:\Data_OM\Rahul1.5T_LOW FA data\'); 
% str=strcat(path,fname); 
% 
% disp(' ');disp(' '); 
% normfactor=input('Enter the normalization peak/mode/mean value from the 
normalization image:  '); 
  
tr=input('Enter TR of the experiment: '); 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
mm=zeros(rows,cols); 
  
  
  
% flag=input(' ENTER 1 for alpha map normalisation: OR 2 for normal T1 map 
calculation: '); 
  
fa=fa*(pi/180); 
   
  
%%%%%%%%%%%%%%%%%% ACTUAL CALCULATION WITH ALPHA MAP COMPENSATION INCLUDED 
for i=1:slices 
  
    %     alphamap=zeros(rows,cols);% IMAGE MATRIX SIZE 
    mat=zeros(rows,cols); % IMAGE MATRIX SIZE 
    xmat=zeros(size(fa,2),rows,cols); % IMAGE MATRIX SIZE 
    ymat=zeros(size(fa,2),rows,cols); % IMAGE MATRIX SIZE 
    %     faimagemat=zeros(size(fa,2),rows,cols); % IMAGE MATRIX SIZE 
  
  
    for j=1:fanumber 
  
  
        if s(j).fpathname(size(s(j).fpathname,2)-5)=='-' 
            firstnum=str2num(s(j).fpathname(size(s(j).fpathname,2)-4)); 
            
mat(:,:)=dicomread(strcat(s(j).fpathname(1,1:(size(s(j).fpathname,2)-
5)),num2str(firstnum+i-1),'.dcm')); 
            mat(:,:)=mat./exp(-TE./t2starcorrection); 
        else 
            firstnum=str2num(s(j).fpathname(size(s(j).fpathname,2)-4))+10; 
            
mat(:,:)=dicomread(strcat(s(j).fpathname(1,1:(size(s(j).fpathname,2)-
6)),num2str(firstnum+i-1),'.dcm')); 
            mat(:,:)=mat./exp(-TE./t2starcorrection); 
        end 
  
  
        faimagemat(j,:,:)=mat; 
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        tmps=sin(fa(j)); 
        tmpt=tan(fa(j)); 
        ymat(j,:,:)=mat./tmps; 
        xmat(j,:,:)=mat./tmpt; 
  
    end 
    clear  mat tmps tmpt; 
  
  
    num=fanumber*sum((xmat.*ymat),1)-(sum(xmat,1).*sum(ymat,1)); 
    din=fanumber*(sum(xmat.^2,1))-(sum(xmat,1)).^2; 
  
   
    b1=num./din; 
  
    b2=(1/fanumber)*(sum(ymat,1)-b1.*sum(xmat,1)); 
  
  
    T1map=-tr./(log(b1)); %%%%% TR OF THE EXPERIMENT 
  
    mm(:,:)=T1map(1,:,:); 
    clear T1map; 
    T1map=mm; 
  
    % Error MATRIX calculation 
  
    yestimate=zeros(size(fa,2),rows,cols); % IMAGE MATRIX SIZE 
  
    for j=1:fanumber 
        num=b2.*sin(fa(j)); 
        din=1-cos(fa(j)).*b1; 
        yestimate(j,:,:)=num./din; 
    end 
    sigma_y_error_estimate=sqrt((1/(fanumber-2))*sum((yestimate-
faimagemat).^2,1)); 
  
    din=fanumber*(sum(xmat.^2,1))-(sum(xmat,1)).^2; 
  
    error_b1=sigma_y_error_estimate.*sqrt(fanumber./din); 
  
    mm(:,:)=zeros(rows,cols); 
    mm(:,:)=din(1,:,:); 
    clear din; 
    din=mm;clear mm; 
  
  
    T1_error=(tr*error_b1)./(b1.*(log(b1)).^2); 
  
    rho_e2=b2./(1-b1); 
  
  
    mm(:,:)=zeros(rows,cols); 
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    mm(:,:)=T1_error(1,:,:); 
    clear T1_error error_b1; 
    T1_error=mm; 
  
  
    curntfname=strcat(s(1).fpathname(1,(1:size(s(1).fpathname,2)-7)),'T1_map-
',num2str(i),'.ima'); 
    writeima(curntfname, T1map); 
  
    curntfname=strcat(s(1).fpathname(1,(1:size(s(1).fpathname,2)-
7)),'T1_errmap_mult10-',num2str(i),'.ima'); 
    writeima(curntfname, T1_error*10); 
  
  
end 
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APPENDIX B 
CACULATED RELAXIVITY OF 5.1 AND 5.1–HSA AT  
DIFFERENT MAGNETIC FIELD STRENGTHS  
Pertinent equations: 
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The calculated relaxivity decreases from 1.4 T to 11.7 T (Table B.1). Assumptions made in the 
calculations are that the electronic parameters, v and Δ
2
, do not change with magnetic field and that the 
values of v and Δ
2
 that were measured at 0.34 T are valid at higher field strengths. It was also assumed 
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that the R for the biphenyl-modified cryptate in the presence of HSA is the same as that of MS-325 in 
the presence of HSA at 37 C. 
Constants           References 
m 4.0 × 10
–8
 this work 
q 1  this work 
γI 2.67 × 10
8
 http://physics.nist.gov/cgi-bin/cuu/Value?gammap 
g 2  http://physics.nist.gov/cgi-bin/cuu/Value?gem|search_for=all! 
μB 9.27 × 10
–24
 http://physics.nist.gov/cgi-bin/cuu/Value?mub 
rEu–H        3.22 × 10
–10
 L. Burai, É. Tóth, S. Seibig, R. Scopelliti, A. E. Merbach, Chem. Eur. J. 6 
(2000) 3761–3770. 
μo 1.00 × 10
–7
 http://physics.nist.gov/cgi-bin/cuu/Value?mu0 
γS 1.76 × 10
11
 L. Burai, É. Tóth, S. Seibig, R. Scopelliti, A. E. Merbach, Chem. Eur. J. 6 
(2000) 3761–3770. 
R          1.33 × 10
–8
 MS-325 with HSA from P. Caravan, N. J. Cloutier, M. T. Greenfield, S. 
A. McDermid, S. U. Dunham, J. W. M. Bulte, J. C. Amedio, Jr., R. J. 
Looby, R. M. Supkowski, W. DeW. Horrocks, Jr., T. J. McMurry, R. B. 
Lauffer, J. Am. Chem. Soc. 124 (2002) 3152–3162. 
Δ2 2.10 × 1019 Eu2+[2.2.2]cryptate from L. Burai, R. Scopelliti, É. Tóth, Chem. Commun. 
(2002) 2366–2367. 
v 1.70 × 10
–11
 Eu
2+
[2.2.2]cryptate from L. Burai, R. Scopelliti, É. Tóth, Chem. Commun. 
(2002) 2366–2367. 
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Table B.1. Calculated relaxivity values of 5.1 in the presence of HSA at different field strengths 
at 37 C. 
 
Field Strength (T) Relaxivity (mM
–1
s
–1
) 
1.4 16.10 
3 3.80 
7 0.71 
9.4 0.40 
11.7 0.26 
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ABSTRACT 
STUDIES ON THE PHYSICOCHEMICAL PROPERTIES OF 
Eu
2+
 CRYPTATES: IMPLICATIONS TO CONTRAST 
AGENTS FOR MAGNETIC RESONANCE IMAGING 
by 
JOEL GARCIA 
May 2013 
Advisor: Professor Matthew J. Allen 
Major: Chemistry  
Degree: Doctor of Philosophy 
Magnetic resonance imaging (MRI) is a powerful medical imaging technique that can be 
enhanced using metal complexes called contrast agents. Most clinically approved contrast 
agents contain Gd
3+
. However, the efficiency (also known as relaxivity) of these Gd
3+
-
containing complexes decreases as field strength increases, and in the ultra-high field 
strength regime, the relaxivity of these complexes is decreased considerably. Because of 
the slow water-exchange rate of most Gd
3+
-containing complexes (~10
6
 s
–1
), I used Eu
2+
 
instead of Gd
3+ 
 and adapted the ligand modification strategies that have been used for 
Gd
3+
-containing contrast agents to my Eu
2+
-containing complexes. Eu
2+
 is isoelectronic to 
Gd
3+
 and has fast water-exchange rate (~10
9
 s
–1
); however, the propensity of Eu
2+ 
to 
oxidize in aerobic conditions limits its utility. Earlier work in the Allen lab demonstrated 
that modified cryptands can stabilize the divalent state of Eu. Because of the favorable 
properties of Eu
2+
 and the ability of cryptands to oxidatively stabilize Eu
2+
, I hypothesized 
that Eu
2+
-containing cryptates could serve as good candidates for use as contrast agents for 
MRI. Relaxometric studies revealed higher efficacy of small Eu
2+
-containing cryptates 
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compared to the clinically approved contrast agent gadolinium(III) 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetate at ultra-high field strengths. Also, an increase 
in relaxivity with increasing field strength was observed for these cryptates. Further, the 
relaxivity of Eu
2+
-containing cryptates decreases as temperature increases, but is not 
affected by changes in pH in a physiologically relevant range.  
Variable-temperature 
17
O NMR and electron paramagnetic resonance spectroscopy 
were used to understand these observations in relaxivity. Variable-temperature 
17
O NMR 
experiments revealed the presence of two inner-sphere water molecules and fast water-
exchange rates (~10
7–108 s–1) for small Eu2+-containing cryptates. With the relaxivity and 
17
O NMR and EPR data, rotational-correlation rates for these cryptates were estimated and 
were found to limit relaxivity. 
In addition to relaxometric studies, transmetallation experiments were performed in 
the presence of Ca
2+
, Mg
2+
, and Zn
2+
 because of their relative abundance in plasma and the 
affinity of these ions for ligands. The transmetallation experiments demonstrated that 
amine-based cryptates are stable to transmetallation in the presence of Ca
2+
, Mg
2+
, and 
Zn
2+
 and are more stable than the clinically approved gadolinium(III) 
diethylenetriaminepentaacetate, a promising result for their potential use for in vivo 
applications. 
Because relaxivity of small Eu
2+
-containing cryptates increases with molecular 
weight, I also investigated the effect of albumin on the relaxivity of a biphenyl-containing 
cryptate. While relaxivity enhancement was observed in the presence of albumin at 1.4 T, 
the relaxivity of the biphenyl-based cryptate in the presence of albumin at 3, 7, 9.4, and 
11.7 T was lower compared to in the absence of albumin. This decrease in relaxivity was 
attributed to a displacement of one inner-sphere water molecule upon protein binding. 
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These studies of the physicochemical properties of Eu
2+
-containing cryptates 
provide a better understanding of how relaxivity is influenced by molecular parameters 
including the number of inner-sphere water molecules, water-exchange rate, and rotational-
correlation rate for these cryptates and pave the way for designing more efficient Eu
2+
-
containing cryptates for use as contrast agents for MRI. 
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